

# Dane County Contract Cover Sheet

*Res 395  
significant*

<b>Dept./Division</b>	Medical Examiner
<b>Vendor Name</b>	National Medical Services Inc (NMS Labs)
<b>Vendor MUNIS #</b>	5598
<b>Brief Contract Title/Description</b>	Provide forensic toxicology and expert testimony services.
<b>Contract Term</b>	January 1, 2020-December 31, 2022
<b>Total Contract Amount</b>	\$ 250,000

<b>Contract #</b> <small>Admin will assign</small>	13861
<b>Addendum</b>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
<b>Type of Contract</b>	
<input checked="" type="checkbox"/>	Dane County Contract
<input type="checkbox"/>	Grant
<input type="checkbox"/>	County Lessee
<input type="checkbox"/>	County Lessor
<input type="checkbox"/>	Intergovernmental
<input type="checkbox"/>	Purchase of Property
<input type="checkbox"/>	Property Sale
<input type="checkbox"/>	Other

<b>Purchasing Authority</b>	<input type="checkbox"/> \$10,000 or under – Best Judgment (1 quote required)	
	<input type="checkbox"/> Between \$10,000 – \$36,000 (\$0 – \$25,000 Public Works) (3 quotes required)	
	<input checked="" type="checkbox"/> Over \$36,000 (\$25,000 Public Works) (Formal RFB/RFP required)	<b>RFB/RFP #</b> 119023
	<input type="checkbox"/> Bid Waiver – \$36,000 or under (\$25,000 or under Public Works)	
	<input type="checkbox"/> Bid Waiver – Over \$36,000 (N/A to Public Works)	
	<input type="checkbox"/> N/A – Grants, Leases, Intergovernmental, Property Purchase/Sale, Other	

MUNIS Req.	Org Code	MEDEXAM	Obj Code	30860	Amount	\$ 75,000
Req # 729	Org Code		Obj Code		Amount	\$
Year 2020	Org Code		Obj Code		Amount	\$



<b>Resolution</b>	<b>A resolution is required if the contract exceeds \$100,000 (\$40,000 Public Works). A copy of the Resolution must be attached to the contract cover sheet.</b>	
	<input type="checkbox"/> Contract does not exceed \$100,000 (\$40,000 Public Works) – a resolution is not required.	
	<input checked="" type="checkbox"/> Contract exceeds \$100,000 (\$40,000 Public Works) – resolution required.	<b>Res #</b> 395
	<input checked="" type="checkbox"/> A copy of the Resolution is attached to the contract cover sheet.	<b>Year</b> 19-20

Contract Review/Approvals				
Initials	Dept.	Date In	Date Out	Comments
	Received by DOA			
<i>mlc</i>	Controller	12/6/19	12/6/19	
<i>Qq</i>	Purchasing	12/6/19	12/6/19	
<i>jd</i>	Corporation Counsel	12/4/19	12/6/19	
<i>jd</i>	Risk Management	12/10/19	12/10/19	
	County Executive			

Dane County Dept. Contact Info		Vendor Contact Info	
<b>Name</b>	Barry Irlen, Director of Operations	<b>Name</b>	Eric White
<b>Phone #</b>	608-284-6000	<b>Phone #</b>	215-205-1359
<b>Email</b>	irmen@countyofdane.com	<b>Email</b>	Eric.White@NMSLABS.COM
<b>Address</b>	3111 Luds Lane McFarland WI 53558	<b>Address</b>	200 Welsh Rd Horsham PA 19044



<b>Certification:</b> The attached contract is a:	
<input type="checkbox"/>	Dane County Contract <u>without</u> any modifications.
<input checked="" type="checkbox"/>	Dane County Contract <u>with</u> modifications. The modifications have been reviewed by: Carlos Pabellon
<input type="checkbox"/>	Non-standard contract.

### Contract Cover Sheet Signature

Department Approval of Contract		
<b>Dept. Head / Authorized Designee</b>	<b>Signature</b>	<b>Date</b>
		12-2-19
	<b>Printed Name</b>	
		

### Contracts Exceeding \$100,000

Major Contracts Review – DCO Sect. 25.11(3)

<b>Director of Administration</b>	<b>Signature</b>	<b>Date</b>
		12-4-19
	<b>Comments</b>	
<b>Corporation Counsel</b>	<b>Signature</b>	<b>Date</b>
		12-6-19
	<b>Comments</b>	



DANE COUNTY CONTRACT # 13861



# of Pages Including Schedules: 40  
Expiration Date: December 31, 2022  
Authority: Res. # 395, 19-20  
Department: Medical Examiner  
Maximum Cost: \$250,000  
Registered Agent: Incorp Services Inc.  
Registered Agent Address: 901 S. Whitney Way,  
Madison, WI 53711

**THIS AGREEMENT**, made and entered into, by and between the County of Dane (hereafter referred to as "COUNTY") and National Medical Services, Inc. DBA NMS Labs (hereafter, "PROVIDER"),

**WITNESSETH:**

**WHEREAS** COUNTY, whose address is 3111 Luds Lane, McFarland WI 53558, desires to purchase services from PROVIDER for the purpose of providing forensic toxicology services; and

**WHEREAS** PROVIDER, whose address is 200 Welsh Road, Horsham, PA 19044, is able and willing to provide such services;

**NOW, THEREFORE**, in consideration of the above premises and the mutual covenants of the parties hereinafter set forth, the receipt and sufficiency of which is acknowledged by each party for itself, COUNTY and PROVIDER do agree as follows:

**I. TERM:**

The term of this Agreement shall commence as of the date by which all parties have executed this Agreement and shall end as of the EXPIRATION DATE set forth on page 1 hereof, unless sooner agreed to in writing by the parties. PROVIDER shall complete its obligations under this Agreement not later than the EXPIRATION DATE. Upon failure of PROVIDER to complete its obligation set forth herein by the EXPIRATION DATE, COUNTY may invoke the penalties, if any, set forth in this document and its attachments.

**II. SERVICES:**

A. PROVIDER agrees to provide the services detailed in the bid specifications, if any; the request for proposals (RFP) and PROVIDER's response thereto, if any; and on the attached Schedule A, which is fully incorporated herein by reference. In the event of a conflict between or among the bid specifications, the RFP or responses thereto, or the terms of Schedule A or any of them, it is agreed that the terms of Schedule A, to the extent of any conflict, are controlling.

B. PROVIDER shall commence, carry on and complete its obligations under this Agreement with all deliberate speed and in a sound, economical and efficient manner, in accordance with this Agreement and all applicable laws. In providing services under this Agreement, PROVIDER agrees to cooperate with the various departments, agencies, employees and officers of COUNTY.

- C. PROVIDER agrees to secure at PROVIDER's own expense all personnel necessary to carry out PROVIDER's obligations under this Agreement. Such personnel shall not be deemed to be employees of COUNTY nor shall they or any of them have or be deemed to have any direct contractual relationship with COUNTY.

**III. ASSIGNMENT/TRANSFER:**

PROVIDER shall neither assign nor transfer any interest or obligation in this Agreement, without the prior written consent of COUNTY unless otherwise provided herein, provided that claims for money due or to become due PROVIDER from COUNTY under this Agreement may be assigned to a bank, trust company or other financial institution without such approval if and only if the instrument of assignment contains a provision substantially to the effect that it is agreed that the right of the assignee in and to any moneys due or to become due to PROVIDER shall be subject to prior claims of all persons, firms and corporations for services rendered or materials supplied for the performance of the work called for in this Agreement. PROVIDER shall promptly provide notice of any such assignment or transfer to COUNTY.

**IV. TERMINATION:**

A. Failure of PROVIDER to fulfill any of its obligations under this Agreement in a timely manner, or violation by PROVIDER of any of the covenants or stipulations of this Agreement, shall constitute grounds for COUNTY to terminate this Agreement by giving a thirty (30) day written notice to PROVIDER.

D. The following shall constitute grounds for immediate termination:

1. violation by PROVIDER of any State, Federal or local law, or failure by PROVIDER to comply with any applicable States and Federal service standards, as expressed by applicable statutes, rules and regulations.
2. failure by PROVIDER to carry applicable licenses or certifications as required by law.
3. failure of PROVIDER to comply with reporting requirements contained herein.
4. inability of PROVIDER to perform the work provided for herein.

C. Failure of the Dane County Board of Supervisors or the State or Federal Governments to appropriate sufficient funds to carry out COUNTY's obligations hereunder, shall result in automatic termination of this Agreement as of the date funds are no longer available, without notice.

D. In the event COUNTY terminates this Agreement as provided herein, all finished and unfinished documents, services, papers, data, products, and the like prepared, produced or made by PROVIDER under this Agreement shall at the option of COUNTY become the property of COUNTY, and PROVIDER shall be entitled to receive just and equitable compensation, subject to any penalty, for any satisfactory work completed on such documents, services, papers, data, products or the like. Notwithstanding the above, PROVIDER shall not be relieved of liability to COUNTY for damages sustained by COUNTY by virtue of any breach of this Agreement by PROVIDER, and COUNTY may withhold any payments to PROVIDER for the purpose of offset.

**V. PAYMENT:**

COUNTY agrees to make such payments for services rendered under this Agreement as and in the manner specified herein and in the attached Schedule B, which is fully incorporated herein by reference. Notwithstanding any language to the contrary in this Agreement or its attachments, COUNTY shall never be required to pay more than the sum set forth on page 1 of this Agreement under the heading MAXIMUM COST, for all services rendered by PROVIDER under this Agreement.

**VI. REPORTS:**

PROVIDER agrees to make such reports as are required in the attached Schedule C, which is fully incorporated herein by reference. With respect to such reports it is expressly understood that time is of the essence and that the failure of PROVIDER to comply with the time limits set forth in said Schedule C shall result in the penalties set forth herein.

**VII. DELIVERY OF NOTICE:**

Notices, bills, invoices and reports required by this Agreement shall be deemed delivered as of the date of postmark if deposited in a United States mailbox, first class postage attached, addressed to a party's address as set forth above. It shall be the duty of a party changing its address to notify the other party in writing within a reasonable time.

**VIII. INSURANCE:**

A. PROVIDER shall indemnify, hold harmless and defend COUNTY, its boards, commissions, agencies, officers, employees and representatives against any and all liability, loss (including, but not limited to, property damage, bodily injury and loss of life), damages, costs or expenses which COUNTY, its officers, employees, agencies, boards, commissions and representatives may sustain, incur or be required to pay by reason of PROVIDER's furnishing the services or goods required to be provided under this Agreement, provided, however, that the provisions of this paragraph shall not apply to liabilities, losses, charges, costs, or expenses caused by or resulting from the acts or omissions of COUNTY, its agencies, boards, commissions, officers, employees or representatives. The obligations of PROVIDER under this paragraph shall survive the expiration or termination of this Agreement.

B. In order to protect itself and COUNTY, its officers, boards, commissions, agencies, agents, volunteers, employees and representatives under the indemnity provisions of the subparagraph above, PROVIDER shall, at PROVIDER's own expense, obtain and at all times during the term of this Agreement keep in full force and effect the insurance coverages, limits, and endorsements listed below. When obtaining required insurance under this Agreement and otherwise, PROVIDER agrees to preserve COUNTY's subrogation rights in all such matters that may arise that are covered by PROVIDER's insurance. Neither these requirements nor the COUNTY's review or acceptance of PROVIDER's certificates of insurance is intended to limit or qualify the liabilities or obligations assumed by the PROVIDER under this Agreement. The County expressly reserves the right to require higher or lower insurance limits where County deems necessary.

**Commercial General Liability.**

PROVIDER agrees to maintain Commercial General Liability insurance at a limit of not less than \$1,000,000 per occurrence. Coverage shall include, but not be limited to, Bodily Injury and Property Damage to Third Parties, Contractual Liability, Personal Injury and Advertising Injury Liability, Premises-Operations, Independent PROVIDERs and Subcontractors, and Fire Legal Liability. The policy shall not exclude Explosion, Collapse, and Underground Property Damage Liability Coverage. The policy shall list DANE COUNTY as an Additional Insured.

**Commercial/Business Automobile Liability.**

PROVIDER agrees to maintain Commercial/Business Automobile Liability insurance at a limit of not less than \$1,000,000 Each Occurrence. PROVIDER further agrees coverage shall include liability for Owned, Non-Owned & Hired automobiles. In the event PROVIDER does not own automobiles, PROVIDER agrees to maintain coverage for Hired & Non-Owned Auto Liability, which may be satisfied by way of endorsement to the Commercial General Liability policy or separate Business Auto Liability policy.

**Environmental Impairment (Pollution) Liability**

PROVIDER agrees to maintain Environmental Impairment (Pollution) Liability insurance at a limit of not less than \$1,000,000 per occurrence for bodily injury, property damage, and environmental cleanup costs caused by pollution conditions, both sudden and non-sudden. This requirement can be satisfied by either a separate environmental liability

policy or through a modification to the Commercial General Liability policy. Evidence of either must be provided.

Workers' Compensation.

PROVIDER agrees to maintain Workers Compensation insurance at Wisconsin statutory limits.

Umbrella or Excess Liability.

PROVIDER may satisfy the minimum liability limits required above for Commercial General Liability and Business Auto Liability under an Umbrella or Excess Liability policy. There is no minimum Per Occurrence limit of liability under the Umbrella or Excess Liability; however, the Annual Aggregate limit shall not be less than the highest "Each Occurrence" limit for the Commercial General Liability and Business Auto Liability. PROVIDER agrees to list DANE COUNTY as an "Additional Insured" on its Umbrella or Excess Liability policy.

- C. Upon execution of this Agreement, PROVIDER shall furnish COUNTY with a Certificate of Insurance listing COUNTY as an additional insured and, upon request, certified copies of the required insurance policies. If PROVIDER's insurance is underwritten on a Claims-Made basis, the Retroactive Date shall be prior to or coincide with the date of this Agreement, the Certificate of Insurance shall state that professional malpractice or errors and omissions coverage, if the services being provided are professional services coverage is Claims-Made and indicate the Retroactive Date, PROVIDER shall maintain coverage for the duration of this Agreement and for six (6) years following the completion of this Agreement. PROVIDER shall furnish COUNTY, annually on the policy renewal date, a Certificate of Insurance as evidence of coverage. It is further agreed that PROVIDER shall furnish the COUNTY with a 30-day notice of aggregate erosion, in advance of the Retroactive Date, cancellation, or renewal. It is also agreed that on Claims-Made policies, either PROVIDER or COUNTY may invoke the tail option on behalf of the other party and that the Extended Reporting Period premium shall be paid by PROVIDER. In the event any action, suit or other proceeding is brought against COUNTY upon any matter herein indemnified against, COUNTY shall give reasonable notice thereof to PROVIDER and shall cooperate with PROVIDER's attorneys in the defense of the action, suit or other proceeding. PROVIDER shall furnish evidence of adequate Worker's Compensation Insurance. In case of any sublet of work under this Agreement, PROVIDER shall furnish evidence that each and every subcontractor has in force and effect insurance policies providing coverage identical to that required of PROVIDER. In case of any sublet of work under this Agreement, PROVIDER shall furnish evidence that each and every subcontractor has in force and effect insurance policies providing coverage identical to that required of PROVIDER.
- D. The parties do hereby expressly agree that COUNTY, acting at its sole option and through its Risk Manager, may waive any and all requirements contained in this Agreement, such waiver to be in writing only. Such waiver may include or be limited to a reduction in the amount of coverage required above. The extent of waiver shall be determined solely by COUNTY's Risk Manager taking into account the nature of the work and other factors relevant to COUNTY's exposure, if any, under this Agreement.
- E. *FORCE MAJEURE. PROVIDER shall not be deemed to be in default of any provision of this Agreement, nor be liable for any delay, failure in performance or interruption of services, resulting directly or indirectly from acts of God, embargoes, quarantines, civil or military authority, civil disturbance, insurrection, war, acts of terrorism, fire, other catastrophes or any such other cause beyond its control.*

**IX. NO WAIVER BY PAYMENT OR ACCEPTANCE:**

In no event shall the making of any payment or acceptance of any service or product required by this Agreement constitute or be construed as a waiver by COUNTY of any breach of the covenants of this Agreement or a waiver of any default of PROVIDER and the making of any such payment or acceptance of any such service or product by COUNTY while any such default

or breach shall exist shall in no way impair or prejudice the right of COUNTY with respect to recovery of damages or other remedy as a result of such breach or default.

**X. NON-DISCRIMINATION:**

During the term of this Agreement, PROVIDER agrees not to discriminate on the basis of age, race, ethnicity, religion, color, gender, disability, marital status, sexual orientation, national origin, cultural differences, ancestry, physical appearance, arrest record or conviction record, military participation or membership in the national guard, state defense force or any other reserve component of the military forces of the United States, or political beliefs against any person, whether a recipient of services (actual or potential) or an employee or applicant for employment. Such equal opportunity shall include but not be limited to the following: employment, upgrading, demotion, transfer, recruitment, advertising, layoff, termination, training, rates of pay, and any other form of compensation or level of service(s). PROVIDER agrees to post in conspicuous places, available to all employees, service recipients and applicants for employment and services, notices setting forth the provisions of this paragraph. The listing of prohibited bases for discrimination shall not be construed to amend in any fashion state or federal law setting forth additional bases, and exceptions shall be permitted only to the extent allowable in state or federal law.

**XI. CIVIL RIGHTS COMPLIANCE:**

- A. If PROVIDER has 20 or more employees and receives \$20,000 in annual contracts with COUNTY, the PROVIDER shall submit to COUNTY a current Civil Rights Compliance Plan (CRC) for Meeting Equal Opportunity Requirements under Title VI of the Civil Rights Act of 1964, Section 504 of the Rehabilitation Act of 1973, Title VI and XVI of the Public Service Health Act, the Age Discrimination Act of 1975, the Omnibus Budget Reconciliation Act of 1981 and Americans with Disabilities Act (ADA) of 1990. PROVIDER shall also file an Affirmative Action (AA) Plan with COUNTY in accordance with the requirements of chapter 19 of the Dane County Code of Ordinances. PROVIDER shall submit a copy of its discrimination complaint form with its CRC/AA Plan. The CRC/AA Plan must be submitted prior to the effective date of this Agreement and failure to do so by said date shall constitute grounds for immediate termination of this Agreement by COUNTY. If an approved plan has been received during the previous CALENDAR year, a plan update is acceptable. The plan may cover a two-year period. Providers who have less than twenty employees, but who receive more than \$20,000 from the COUNTY in annual contracts, may be required to submit a CRC Action Plan to correct any problems discovered as the result of a complaint investigation or other Civil Rights Compliance monitoring efforts set forth herein below. If PROVIDER submits a CRC/AA Plan to a Department of Workforce Development Division or to a Department of Health and Family Services Division that covers the services purchased by COUNTY, a verification of acceptance by the State of PROVIDER's Plan is sufficient.
- B. PROVIDER agrees to comply with the COUNTY's civil rights compliance policies and procedures. PROVIDER agrees to comply with civil rights monitoring reviews performed by the COUNTY, including the examination of records and relevant files maintained by the PROVIDER. PROVIDER agrees to furnish all information and reports required by the COUNTY as they relate to affirmative action and non-discrimination. PROVIDER further agrees to cooperate with COUNTY in developing, implementing, and monitoring corrective action plans that result from any reviews.
- C. PROVIDER shall post the Equal Opportunity Policy, the name of PROVIDER's designated Equal Opportunity Coordinator and the discrimination complaint process in conspicuous places available to applicants and clients of services, applicants for employment and employees. The complaint process will be according to COUNTY's policies and procedures and made available in languages and formats understandable to applicants, clients and employees. PROVIDER shall supply to COUNTY's Contract Compliance Officer upon request a summary document of all client complaints related to perceived discrimination in service delivery. These documents shall include names of the involved persons, nature of the complaints, and a description of any attempts made to achieve complaint resolution.



- D. PROVIDER shall provide copies of all announcements of new employment opportunities to COUNTY's Contract Compliance Officer when such announcements are issued.
- E. If PROVIDER is a government entity having its own compliance plan, PROVIDER'S plan shall govern PROVIDER's activities.

**XII. COMPLIANCE WITH FAIR LABOR STANDARDS:**

- A. Reporting of Adverse Findings. During the term of this Agreement, PROVIDER shall report to the County Contract Compliance Officer, within ten (10) days, any allegations to, or findings by the National Labor Relations Board (NLRB) or Wisconsin Employment Relations Commission (WERC) that PROVIDER has violated a statute or regulation regarding labor standards or relations. If an investigation by the Contract Compliance Officer results in a final determination that the matter adversely affects PROVIDER'S responsibilities under this Agreement, and which recommends termination, suspension or cancellation of this agreement, the County may take such action.
- B. Appeal Process. PROVIDER may appeal any adverse finding by the Contract Compliance Officer as set forth in Dane County Ordinances Sec. 25.08(20)(c) through (e).
- C. Notice Requirement. PROVIDER shall post the following statement in a prominent place visible to employees: "As a condition of receiving and maintaining a contract with Dane County, this employer shall comply with federal, state and all other applicable laws prohibiting retaliation for union organizing."

**XIII. MISCELLANEOUS:**

- A. Registered Agent. PROVIDER warrants that it has complied with all necessary requirements to do business in the State of Wisconsin, that the persons executing this Agreement on its behalf are authorized to do so, and, if a corporation, that the name and address of PROVIDER's registered agent is as set forth opposite the heading REGISTERED AGENT on page 1 of this Agreement. PROVIDER shall notify COUNTY immediately, in writing, of any change in its registered agent, his or her address, and PROVIDER's legal status. For a partnership, the term 'registered agent' shall mean a general partner.
- B. Controlling Law and Venue. It is expressly understood and agreed to by the parties hereto that in the event of any disagreement or controversy between the parties, Wisconsin law shall be controlling. Venue for any legal proceedings shall be in the Dane County Circuit Court.
- C. Limitation Of Agreement. This Agreement is intended to be an agreement solely between the parties hereto and for their benefit only. No part of this Agreement shall be construed to add to, supplement, amend, abridge or repeal existing duties, rights, benefits or privileges of any third party or parties, including but not limited to employees of either of the parties.
- D. Entire Agreement. The entire agreement of the parties is contained herein and this Agreement supersedes any and all oral agreements and negotiations between the parties relating to the subject matter hereof. The parties expressly agree that this Agreement shall not be amended in any fashion except in writing, executed by both parties.
- E. Counterparts. The parties may evidence their agreement to the foregoing upon one or several counterparts of this instrument, which together shall constitute a single instrument.



## **SCHEDULE A**

### **Scope of Services**

Provider shall provide forensic toxicology and expert testimony services for the period January 1, 2020-December 31, 2022.

Provider's Labs are operational 24/7 to provide consistent quick turnaround time on comprehensive toxicology, with approximate turnaround time of 10 business days.

Provider shall provide one rotation for a pathology resident for toxicology training per contract year at no charge.

All analytical testing is performed in-house, with no use of an outside reference laboratory for quantitative or conformational testing.

Personalized access to an assigned DirecTox™ for direct phone and email access on case history evaluation, sample collection guidance, test recommendations, Test result review, and Interpretation of findings.

Provider shall provide onsite training at the County for preparation of the project, sample submission, submission, and report delivery.

Prepaid shipping of samples via Federal Express Standard Overnight (next business day) delivery on Monday through Saturday.

Forensic Client Support available via phone and email Monday – Friday 7am – 7:30pm Central Standard Time. Provider also provides a 24/7 Emergency Hotline for Public Health Toxicology Related Emergencies where Toxicology testing and/or consultation may be required.

Dedicated research & development committee (NPS strategy team) structured to offer continuous delivery of toxicology support services of the designer drug toxicology analysis.

Designer drug analysis scope expansion delivered every 9 months to offer the most up-to-date panels for new and emerging drugs.

Access to Provider's comprehensive testing catalog of over 2,700 different tests, with specimen storage on all submitted specimens for twelve (12) months.

Provider is accredited by ISO/IEC 17025:2017 for:

- Toxicology: ANAB (ANSI/ASQ National Accreditation Board) and ABFT (American Board of Forensic Toxicology)

- Seized Drugs and Biology (DNA & Serology): ANAB (ANSI/ASQ National Accreditation Board) and FBI QAS (FBI Quality Assurance Standards – applicable to DNA only)

### Staff Qualifications

Provider employs more than 250 highly trained professionals at our Headquarters and Laboratory at 200 Welsh Road, Horsham, PA 19044. All testing for County will be performed at this location.

### Forensic Client Support Specialists

Provider's Client Support department and will fulfill the expectations and requirements and direct access to a regional toxicologist as well as Toxicologist of the Day for support. Provider's Client Support department is available Monday through Friday to provide support to County in resolving service needs, problems, concerns and general inquiries received daily. Other duties include providing turnaround times on County's cases, adding on additional testing as needed, and assisting the County in obtaining interpretation of results. Provider's staff can also assist in online ordering and inventory control and accessing reports response time for phone inquiries is typically immediate. Support is available by phone at (866) 522-2216 during the following hours: Monday through Friday 7:00 am - 7:30 p.m. Central Time.

Provider's Client Support is available via e-mail at [forensics@nmslabs.com](mailto:forensics@nmslabs.com). This e-mail is checked a minimum of every 30 minutes for activity during client support working hours. Provider's client support staff can handle routine inquiries such as result status, test ordering, expected turnaround time, adding testing to existing cases, appropriate sample requirements, handling and packaging. Provider's client support is also able to handle explanation of Provider's scope of services. If the incoming question from the County is outside of the area of responsibility of Provider's client support staff, they will contact the appropriate Provider staff member for immediate follow up. Provider's client services has a maximum response time of 2 hours during normal business times for email inquiries.

### Toxicologist Consultation

Provider has a Toxicologist of the Day (TOD). The TOD is available by phone Monday through Friday during routine business hours and can be contacted by calling (866) 522-2216. This assigned toxicologist has their work schedule cleared for their assigned day so that they are available for clients. Toxicologists are also available via e-mail.

### Expert Services

Provider's Expert Services Manager will assist in the needs concerning testimony (e.g. subpoenas, litigation packages, and scheduling testimony).

Provider's Expert Services department with (4) dedicated team members is available Monday through Friday to assist in the needs concerning testimony (e.g. subpoenas, litigation packages, and scheduling testimony). Provider's expert services staff is available by phone at 844-276-0768 during the following hours: Monday through Friday 7:00 am - 4:30 p.m. Central Time

### Expert Consultation

Provider's Expert Services Department will manage the delivery of on-site testimony, video or telephone testimony, conferences, litigation package requests, depositions and other services to assist the Dane County Medical Examiner's litigation. In the event that on-site testimony is requested, Provider's Lab (Horsham, PA) is located within one (1) day travel time to Dane County. Provider's scientists are expert in communicating complex ideas to a non-scientific audience.

### Forensic Toxicology Personnel and Key Scientific Staff

Provider has an experienced, well-respected professional staff of Forensic toxicologists that will oversee the analysis of samples received from the Dane County Medical Examiner's Office. Provider's analytical services are supported by a staff of a minimum of 7 Ph.D.-level forensic toxicologists, 6 of which are ABFT Board Certified Forensic Toxicologists. They are responsible for the daily technical, administrative and consultative needs of our forensic clients. Provider's team of qualified professionals has the full capability of providing expert testimony regarding our analytical methods, principles, pharmacokinetic and pharmacodynamic properties for all drugs detected in a sample.

### Testing Turnaround Time

Provider provides quantitated results on forensic postmortem panel tests within 2 weeks on average from the time of receipt.

Esoteric and special request testing may exceed 10 business days.

Provider has the capacity to handle at least 2000 postmortem cases per month and has ample capacity and flexibility to increase volumes if necessary to support any mass fatality related cases.

### Testing Capabilities

Provider has the resources to perform analysis for over 2,700 therapeutic drugs, illicit drugs and other drugs of abuse and their metabolites (such as Benzoylcegonine and Cocaethylene), newly emerging synthetic designer drug compounds (synthetic cannabinoids, bath salts, psycho active stimulants), metals, poisons and other toxic compounds. Analysis can be performed on routine and non-routine samples including:

- Fluids – blood, serum, plasma, urine, vitreous, gastric, bile
- Solids – tissues, all solid organs, bone, injection sites, hair, nails, teeth, decomposed tissue, embalmed bodies, exhumed bodies, insect larvae, bone marrow
- Biological stains on materials (clothing, paper, sheets, carpeting, etc.) for presence of compounds of toxicological interest
- Non Biological Testing capabilities – pills, syringes and other drug paraphernalia
- Documentable proof of method development capabilities for unique analytes

The laboratory results will be reported qualitatively as well as quantitatively, when indicated. The sensitivity of the test and related reporting limit will be referenced in an Analysis Summary included with each report.

The following is a list of the analytical techniques in general use by Provider for screening and confirmation testing:

### Screening

ELISA (Enzyme Linked Immunosorbent Assay) EMIT (Enzyme Multiplied Immunoassay Technique) FPIA (Fluorescence Polarized Immunoassay)

TLC (Thin-layer Chromatography) Microdiffusion Spectrophotometry

LC/MS/MS-TOF (Liquid Chromatography/Mass Spectrometry/Mass Spectrometry/Time of Flight) LC/MS/MS (Liquid Chromatography/Mass Spectrometry/Mass Spectrometry)

HPLC (High Performance Liquid Chromatography) with various forms of detection (UV, Fluorescence, Electrochemical)

GC/MS (Gas Chromatography/Mass Spectrometry)

GC (Gas Chromatography) with various forms of detection (NPD, FID, ECD) ICP/MS (Inductively Coupled Plasma Mass Spectrometry)

GFAAS (Graphite Furnace Atomic Absorption Spectrophotometry)

### Confirmation

LC/MS/MS (Liquid Chromatography/Mass Spectrometry/Mass Spectrometry)

LC/MS/MS-TOF (TOF = Time of Flight)

GC/MS (Gas Chromatography/Mass Spectrometry) ICP/MS (Inductively Coupled Plasma Mass Spectrometry)

Provider shall provide existing methods for toxicology and drug identification upon request for the analyte and quantitation capabilities. Provider utilizes two independent testing methods as part of the normal operating procedure.

All retesting and other work done as a result of errors shall be paid for by Provider.

## **SCHEDULE B**

### **Pricing Structure and Payment**

Following is pricing and scope of testing (including reporting limits and methodology) for:

- 8041B Basic Postmortem Panel (Drugs of Abuse) with Vitreous Alcohol Confirmation (Blood only)
- 8051 Basic Postmortem Panel (Drugs of Abuse) (All other matrices: Serum/Plasma, Urine, Fluid, Tissue)
- 8042B Expanded Postmortem Panel (Comprehensive) with Vitreous Alcohol Confirmation (Blood only)
- 8052 Expanded Postmortem Panel (Comprehensive) All other matrices: Serum/Plasma, Urine, Fluid, Tissue)
- 8054B Expanded with NPS Postmortem Panel
- 9566B Synthetic Cannabinoids (add-on)
- 8155B Designer Opioids (add-on)
- 8756 Novel Psychoactive Substances (NPS) Screen 1
- 8050U Postmortem, Urine Screen Add-on (6-MAM Quantification only)
- 1919FL Electrolytes and Glucose Panel (Vitreous), Fluid
- 1611B Tetrafluoroethane and Difluoroethane Panel, Blood
- 1002B Carbon Monoxide Exposure Screen, Blood

Test codes that are not specifically quoted in this RFP response are listed in our 2019 Fee Schedule. Volume discounting may be available for high volume tests.

NMS Labs will supply the Dane County Medical Examiner with commercially manufactured and quality controlled specimen collection kits specific for forensic cases along with preprinted analysis requisition forms with an area to document chain of custody handling.

Specimens will be transported at the expense of NMS Labs under full chain of custody via Federal Express Standard Overnight service using preprinted shipping airbills and courier supplies provided by NMS Labs.

Samples will be retained for a period of one (1) year at Provider's Labs. The samples will be held in a secured freezer.

Pricing is valid for the first term of the contract January 1, 2020-December 31, 2022. Year 4 of the contract (January 1, 2023-December 31, 2023) will have a 3% increase and Year 5 (January 1, 2024-December 31, 2024) will have a 3% increase.

Acocde	Description	Scope	Test Price
8041B	Basic Postmortem Panel (Drugs of Abuse) with vitreous alcohol confirmation reflex	Amphetamines, alcohol, acetone, isopropyl alcohol, methanol, barbiturates, benzodiazepines, cocaine, cannabinoids, phencyclidine, propoxyphene, opiates, buprenorphine, and fentanyl, vitreous alcohol confirmation (8041B, blood only)	Blood (8041B): \$112 Fluid (8051FL): \$170 Serum/Plasma (8051SP): \$112 Tissue (8051TI): \$180 Urine (8051U): \$112
8042B	Expanded Postmortem Toxicology Panel (Comprehensive) with vitreous alcohol confirmation reflex	Alcohols plus pre-defined selection of abused drugs (including novel psychoactive substances), therapeutic drugs or metabolites, vitreous alcohol confirmation (8042B, blood only)	Blood (8042B): \$169 Fluid (8052FL): \$390 Serum/Plasma (8052SP): \$169 Tissue (8052TI): \$400 Urine (8052U): \$169
8050U	Postmortem, Urine, Screen Add-on (6-MAM Quantification only)	Includes screening analysis of urine for illicit drugs of abuse with quantitative testing 6-MAM. (Can be ordered in conjunction with the Basic or Expanded Blood panels)	Urine: \$0
53249FL	Alcohol confirmation reflex vitreous fluid	Alcohol confirmation reflex testing from blood alcohol positive samples into vitreous fluid	Fluid: \$0
8054B	Postmortem Expanded with NPS Toxicology Panel	All compounds within the 8042B Expanded panel with an Additional 50+ Designer Opiates, Designer Benzo, and NPS compounds	Blood: \$553
9566B	Synthetic Cannabinoids, Blood, Panel	Panel currently includes 26 compounds and is updated regularly as additional compounds are discovered.	Blood: \$165
8155B	Designer Opioids Panel (add-on)	Panel currently includes 21 compounds and is updated regularly as additional compounds are discovered. Urine panel is qualitative.	Blood: \$155 Serum/Plasma: \$155 Urine: \$155
8756	Novel Psychoactive Substances (NPS) Screen 1 Panel	Over 50 of the most relevant novel psychoactive substance compounds.	Blood: \$258 Serum/Plasma: \$258 Urine: \$258
1919FL	Electrolytes & Glucose Panel (Vitreous)	Chloride, Creatinine, Glucose, Potassium, Sodium, and Urea Nitrogen	Fluid: \$62
1611B	Tetrafluoroethane and Difluoroethane Panel, Blood	1,1-Difluoroethane, 1,1,1,2-Tetrafluoroethane	Blood: \$351
1002B	Carbon Monoxide Exposure Panel, Blood	Carboxyhemoglobin (COHb)	Blood: \$123



Acode	Description	Scope	Test Price
8041B	Basic Postmortem Panel (Drugs of Abuse)	Amphetamines, alcohol, acetone, isopropyl alcohol, methanol, barbiturates, benzodiazepines, cocaine, cannabinoids, phencyclidine, propoxyphene, opiates, buprenorphine, and fentanyl, vitreous alcohol confirmation (8041B, blood only)	Blood: \$112 Fluid (8051FL): \$170 Serum/Plasma (8051SP): \$112 Tissue (8051TI): \$180 Urine (8051U): \$112

8041B Postmortem, Basic, Blood scope of testing:

8041B Confirmation Compound	Confirmation Method	Confirmation Reporting Limit	Compound Class	Screening Method
11-Hydroxy Delta-9 THC	LC-MS/MS	1 ng/mL	Cannabinoids	ELISA
6-Monoacetylmorphine - Free	LC-MS/MS	1 ng/mL	Opiates - Free (Unconjugated)	ELISA
7-Amino Clonazepam	LC-MS/MS	5 ng/mL	Benzodiazepines	ELISA
Acetone	Headspace GC	5 mg/dL	Alcohols and Acetone	Headspace GC
Acetyl Fentanyl	LC-MS/MS	0.1 ng/mL	Fentanyl and Acetyl Fentanyl	ELISA
Alpha-Hydroxylprazolam	LC-MS/MS	5 ng/mL	Benzodiazepines	ELISA
Alprazolam	LC-MS/MS	5 ng/mL	Benzodiazepines	ELISA
Amobarbital	GC/MS	0.2 mcg/mL	Barbiturates	ELISA
Amphetamine	LC-MS/MS	5 ng/mL	Amphetamines	ELISA
Benzoylcegonine	GC/MS	50 ng/mL	Cocaine and Metabolites	ELISA
Buprenorphine - Free	LC-MS/MS	0.5 ng/mL	Buprenorphine and Metabolite - Free (Unconjugated)	ELISA
Butabarbital	GC/MS	0.2 mcg/mL	Barbiturates	ELISA
Butalbital	GC/MS	0.2 mcg/mL	Barbiturates	ELISA
Chlordiazepoxide	LC-MS/MS	20 ng/mL	Benzodiazepines	ELISA
Clobazam	LC-MS/MS	20 ng/mL	Benzodiazepines	ELISA
Clonazepam	LC-MS/MS	2 ng/mL	Benzodiazepines	ELISA
Cocaeethylene	GC/MS	20 ng/mL	Cocaine and Metabolites	ELISA
Cocaine	GC/MS	20 ng/mL	Cocaine and Metabolites	ELISA
Codeine - Free	LC-MS/MS	5 ng/mL	Opiates - Free (Unconjugated)	ELISA
Delta-9 Carboxy THC	LC-MS/MS	5 ng/mL	Cannabinoids	ELISA
Delta-9 THC	LC-MS/MS	0.5 ng/mL	Cannabinoids	ELISA
Desalkylflurazepam	LC-MS/MS	5 ng/mL	Benzodiazepines	ELISA
Diazepam	LC-MS/MS	20 ng/mL	Benzodiazepines	ELISA
Dihydrocodeine / Hydrocodol - Free	LC-MS/MS	5 ng/mL	Opiates - Free (Unconjugated)	ELISA

8041B Confirmation Compound	Confirmation Method	Confirmation Reporting Limit	Compound Class	Screening Method
EDDP	LC-MS/MS	20 ng/mL	Methadone and Metabolite	ELISA
Ephedrine	LC-MS/MS	5 ng/mL	Amphetamines	ELISA
Estazolam	LC-MS/MS	5 ng/mL	Benzodiazepines	ELISA
Ethanol	Headspace GC	10 mg/dL	Alcohols and Acetone	Headspace GC
Fentanyl	LC-MS/MS	0.1 ng/mL	Fentanyl and Acetyl Fentanyl	ELISA
Flurazepam	LC-MS/MS	2 ng/mL	Benzodiazepines	ELISA
Hydrocodone - Free	LC-MS/MS	5 ng/mL	Opiates - Free (Unconjugated)	ELISA
Hydromorphone - Free	LC-MS/MS	1 ng/mL	Opiates - Free (Unconjugated)	ELISA
Hydroxyethylflurazepam	LC-MS/MS	5 ng/mL	Benzodiazepines	ELISA
Hydroxytriazolam	LC-MS/MS	5 ng/mL	Benzodiazepines	ELISA
Isopropanol	Headspace GC	5 mg/dL	Alcohols and Acetone	Headspace GC
Lorazepam	LC-MS/MS	5 ng/mL	Benzodiazepines	ELISA
MDA	LC-MS/MS	5 ng/mL	Amphetamines	ELISA
MDEA	LC-MS/MS	5 ng/mL	Amphetamines	ELISA
MDMA	LC-MS/MS	5 ng/mL	Amphetamines	ELISA
Methadone	LC-MS/MS	20 ng/mL	Methadone and Metabolite	ELISA
Methamphetamine	LC-MS/MS	5 ng/mL	Amphetamines	ELISA
Methanol	Headspace GC	5 mg/dL	Alcohols and Acetone	Headspace GC
Midazolam	LC-MS/MS	5 ng/mL	Benzodiazepines	ELISA
Morphine - Free	LC-MS/MS	5 ng/mL	Opiates - Free (Unconjugated)	ELISA
Norbuprenorphine - Free	LC-MS/MS	0.5 ng/mL	Buprenorphine and Metabolite - Free (Unconjugated)	ELISA
Nordiazepam	LC-MS/MS	20 ng/mL	Benzodiazepines	ELISA
Norfentanyl	LC-MS/MS	0.2 ng/mL	Fentanyl and Acetyl Fentanyl	ELISA
Norpseudoephedrine	LC-MS/MS	5 ng/mL	Amphetamines	ELISA
Oxazepam	LC-MS/MS	20 ng/mL	Benzodiazepines	ELISA
Oxycodone - Free	LC-MS/MS	5 ng/mL	Opiates - Free (Unconjugated)	ELISA
Oxymorphone - Free	LC-MS/MS	1 ng/mL	Opiates - Free (Unconjugated)	ELISA
Pentobarbital	GC/MS	0.2 mcg/mL	Barbiturates	ELISA
Phencyclidine	LC-MS/MS	5 ng/mL	Phencyclidine	ELISA
Phenobarbital	GC/MS	0.5 mcg/mL	Barbiturates	ELISA
Phentermine	LC-MS/MS	5 ng/mL	Amphetamines	ELISA
Phenylpropanolamine	LC-MS/MS	5 ng/mL	Amphetamines	ELISA
Pseudoephedrine	LC-MS/MS	5 ng/mL	Amphetamines	ELISA
Secobarbital	GC/MS	0.2 mcg/mL	Barbiturates	ELISA
Temazepam	LC-MS/MS	20 ng/mL	Benzodiazepines	ELISA
Triazolam	LC-MS/MS	2 ng/mL	Benzodiazepines	ELISA

Accode	Description	Scope	Test Price
8042B	Expanded Postmortem Toxicology Panel (Comprehensive)	Alcohols plus pre-defined selection of abused drugs ( <i>including novel psychoactive substances</i> ), therapeutic drugs or metabolites, vitreous alcohol confirmation (8042B, blood only)	Blood: \$169 Fluid (8052FL): \$390 Serum/Plasma (8052SP): \$169 Tissue (8052TI): \$400 Urine (8052U): \$169

8042B Postmortem, Expanded, Blood scope of testing:

8042B Confirmation Compound	Confirmation Method	Confirmation Reporting Limit	Compound Class	Screening Method
10-Hydroxycarbazepine	LC-MS/MS	0.5 mcg/mL	Oxcarbazepine/Eslicarbazepine Acetate as Metabolite	LC/TOF-MS
11-Hydroxy Delta-9 THC	LC-MS/MS	1 ng/mL	Cannabinoids	ELISA
2-Furanylfentanyl	LC-MS/MS	0.05 ng/mL	Designer Opioids (2018 Scope)	LC/TOF-MS
6-Beta-Naltrexol - Free	LC-MS/MS	0.5 ng/mL	Naltrexone and Metabolite - Free (Unconjugated)	LC/TOF-MS
6-Monoacetylmorphine - Free	LC-MS/MS	1 ng/mL	Opiates - Free (Unconjugated)	LC/TOF-MS
7-Amino Clonazepam	LC-MS/MS	5 ng/mL	Benzodiazepines	LC/TOF-MS
7-Amino Flunitrazepam	LC-MS/MS	2 ng/mL	Flunitrazepam and Metabolites	LC/TOF-MS
9-Hydroxyrisperidone	LC-MS/MS	1 ng/mL	Risperidone and Metabolite	LC/TOF-MS
Acetaminophen	LC-MS/MS	0.5 mcg/mL	Acetaminophen	LC/TOF-MS
Acetone	Headspace GC	5 mg/dL	Alcohols and Acetone	Headspace GC
Acetyl Fentanyl	LC-MS/MS	0.1 ng/mL	Fentanyl and Acetyl Fentanyl	LC/TOF-MS
Acryl Fentanyl	LC-MS/MS	0.05 ng/mL	Designer Opioids (2018 Scope)	LC/TOF-MS
Alfentanil	LC-MS/MS	0.1 ng/mL	Alfentanil and Sufentanil	LC/TOF-MS
Alpha-Hydroxyalprazolam	LC-MS/MS	5 ng/mL	Benzodiazepines	LC/TOF-MS
Alprazolam	LC-MS/MS	5 ng/mL	Benzodiazepines	LC/TOF-MS
Amitriptyline	GC	20 ng/mL	Amitriptyline and Metabolite	LC/TOF-MS
Amobarbital	GC/MS	0.2 mcg/mL	Barbiturates	ELISA
Amoxapine	LC-MS/MS	10 ng/mL	Amoxapine	LC/TOF-MS
Amphetamine	LC-MS/MS	5 ng/mL	Amphetamines	LC/TOF-MS
Aripiprazole	LC-MS/MS	20 ng/mL	Aripiprazole	LC/TOF-MS
Atomoxetine	GC/MS	20 ng/mL	Atomoxetine	LC/TOF-MS
BZP	GC/MS	10 ng/mL	Piperazine Designer Drugs	LC/TOF-MS
Benzoyllecgonine	GC/MS	50 ng/mL	Cocaine and Metabolites	LC/TOF-MS
Benztropine	LC-MS/MS	1 ng/mL	Benztropine	LC/TOF-MS
Brompheniramine	GC	40 ng/mL	Brompheniramine	LC/TOF-MS

8042B Confirmation Compound	Confirmation Method	Confirmation Reporting Limit	Compound Class	Screening Method
Bupivacaine	GC	0.1 mcg/mL	Bupivacaine	LC/TOF-MS
Buprenorphine - Free	LC-MS/MS	0.5 ng/mL	Synthetic Opioids - Free (Unconjugated)	LC/TOF-MS
Bupropion	LC-MS/MS	10 ng/mL	Bupropion and Metabolite	LC/TOF-MS
Buspirone	LC-MS/MS	0.5 ng/mL	Buspirone	LC/TOF-MS
Butabarbital	GC/MS	0.2 mcg/mL	Barbiturates	ELISA
Butalbital	GC/MS	0.2 mcg/mL	Barbiturates	ELISA
Butorphanol - Free	LC-MS/MS	0.5 ng/mL	Synthetic Opioids - Free (Unconjugated)	LC/TOF-MS
Butylone	LC-MS/MS	10 ng/mL	Substituted Cathinone	LC/TOF-MS
Butyrylfentanyl	LC-MS/MS	0.05 ng/mL	Designer Opioids (2018 Scope)	LC/TOF-MS
Carbamazepine	LC-MS/MS	0.2 mcg/mL	Carbamazepine and Metabolite	LC/TOF-MS
Carbamazepine-10,11-Epoxyde	LC-MS/MS	0.2 mcg/mL	Carbamazepine and Metabolite	LC/TOF-MS
Carfentanil	LC-MS/MS	0.05 ng/mL	Designer Opioids (2018 Scope)	LC/TOF-MS
Carisoprodol	GC/MS	0.2 mcg/mL	Carisoprodol and Metabolite	LC/TOF-MS
Chlordiazepoxide	LC-MS/MS	20 ng/mL	Benzodiazepines	LC/TOF-MS
Chlorpheniramine	LC-MS/MS	10 ng/mL	Chlorpheniramine	LC/TOF-MS
Chlorpromazine	GC	20 ng/mL	Chlorpromazine	LC/TOF-MS
Citalopram / Escitalopram	LC-MS/MS	5 ng/mL	Citalopram	LC/TOF-MS
Clobazam	LC-MS/MS	20 ng/mL	Benzodiazepines	LC/TOF-MS
Clomipramine	GC	20 ng/mL	Clomipramine and Metabolite	LC/TOF-MS
Clonazepam	LC-MS/MS	2 ng/mL	Benzodiazepines	LC/TOF-MS
Clonazolam	LC-MS/MS	5 ng/mL	Designer Benzodiazepines	LC/TOF-MS
Clonidine	LC-MS/MS	0.1 ng/mL	Clonidine	LC/TOF-MS
Clozapine	LC-MS/MS	20 ng/mL	Clozapine and Metabolite	LC/TOF-MS
Cocaethylene	GC/MS	20 ng/mL	Cocaine and Metabolites	LC/TOF-MS
Cocaine	GC/MS	20 ng/mL	Cocaine and Metabolites	LC/TOF-MS
Codeine - Free	LC-MS/MS	5 ng/mL	Opiates - Free (Unconjugated)	LC/TOF-MS
Cyclobenzaprine	LC-MS/MS	1 ng/mL	Cyclobenzaprine	LC/TOF-MS
Cyclopropylfentanyl	LC-MS/MS	0.05 ng/mL	Designer Opioids (2018 Scope)	LC/TOF-MS
Delorazepam	LC-MS/MS	5 ng/mL	Designer Benzodiazepines	LC/TOF-MS
Delta-9 Carboxy THC	LC-MS/MS	5 ng/mL	Cannabinoids	ELISA
Delta-9 THC	LC-MS/MS	0.5 ng/mL	Cannabinoids	ELISA
Desalkylflurazepam	LC-MS/MS	5 ng/mL	Benzodiazepines	LC/TOF-MS
Desethylildenafil	LC-MS/MS	5 ng/mL	Vardenafil and Metabolite	LC/TOF-MS
Desipramine	GC	20 ng/mL	Imipramine and Metabolite	LC/TOF-MS
Desmethyldomipramine	GC	20 ng/mL	Clomipramine and Metabolite	LC/TOF-MS
Desmethyldoxepin	GC	20 ng/mL	Doxepin and Metabolite	LC/TOF-MS

8042B Confirmation Compound	Confirmation Method	Confirmation Reporting Limit	Compound Class	Screening Method
Desmethylloperamide	LC-MS/MS	5 ng/mL	Loperamide and Metabolite	LC/TOF-MS
Desmethylsertraline	LC-MS/MS	20 ng/mL	Sertraline and Desmethylsertraline	LC/TOF-MS
Desmethyltrimipramine	GC	20 ng/mL	Trimipramine and Metabolite	LC/TOF-MS
Dextro / Levo Methorphan	LC-MS/MS	5 ng/mL	D/L Methorphan, Dextrorphan & Levorphanol	LC/TOF-MS
Dextrorphan / Levorphanol	LC-MS/MS	2 ng/mL	D/L Methorphan, Dextrorphan & Levorphanol	LC/TOF-MS
Diazepam	LC-MS/MS	20 ng/mL	Benzodiazepines	LC/TOF-MS
Dibutylone	LC-MS/MS	10 ng/mL	Substituted Cathinone	LC/TOF-MS
Diclazepam	LC-MS/MS	5 ng/mL	Designer Benzodiazepines	LC/TOF-MS
Dicyclomine	LC-MS/MS	1 ng/mL	Dicyclomine	LC/TOF-MS
Dihydrocodeine / Hydrocodol - Free	LC-MS/MS	5 ng/mL	Opiates - Free (Unconjugated)	LC/TOF-MS
Diltiazem	LC-MS/MS	5 ng/mL	Diltiazem	LC/TOF-MS
Diphenhydramine	LC-MS/MS	50 ng/mL	Diphenhydramine	LC/TOF-MS
Donepezil	LC-MS/MS	5 ng/mL	Donepezil	LC/TOF-MS
Doxepin	GC	20 ng/mL	Doxepin and Metabolite	LC/TOF-MS
Doxylamine	GC	100 ng/mL	Doxylamine	LC/TOF-MS
Duloxetine	LC-MS/MS	30 ng/mL	Duloxetine	LC/TOF-MS
EDDP	LC-MS/MS	20 ng/mL	Methadone and Metabolite	LC/TOF-MS
Ephedrine	LC-MS/MS	5 ng/mL	Amphetamines	LC/TOF-MS
Estazolam	LC-MS/MS	5 ng/mL	Benzodiazepines	LC/TOF-MS
Eszopiclone / Zopiclone	LC-MS/MS	2 ng/mL	Eszopiclone / Zopiclone	LC/TOF-MS
Ethanol	Headspace GC	10 mg/dL	Alcohols and Acetone	Headspace GC
Etizolam	LC-MS/MS	2 ng/mL	Designer Benzodiazepines	LC/TOF-MS
Fentanyl	LC-MS/MS	0.1 ng/mL	Fentanyl and Acetyl Fentanyl	LC/TOF-MS
Flecainide	LC-MS/MS	0.05 mcg/mL	Flecainide	LC/TOF-MS
Flubromazolam	LC-MS/MS	2 ng/mL	Designer Benzodiazepines	LC/TOF-MS
Flunitrazepam	LC-MS/MS	2 ng/mL	Flunitrazepam and Metabolites	LC/TOF-MS
Fluoxetine	GC/MS	20 ng/mL	Fluoxetine and Metabolite	LC/TOF-MS
Fluphenazine	LC-MS/MS	0.5 ng/mL	Fluphenazine	LC/TOF-MS
Flurazepam	LC-MS/MS	2 ng/mL	Benzodiazepines	LC/TOF-MS
Fluvoxamine	GC	10 ng/mL	Fluvoxamine	LC/TOF-MS
Gabapentin	LC-MS/MS	1 mcg/mL	Gabapentin	ELISA
Glimepiride	LC-MS/MS	25 ng/mL	Glimepiride	LC/TOF-MS
Glipizide	LC-MS/MS	40 ng/mL	Hypoglycemics	LC/TOF-MS
Glyburide	LC-MS/MS	40 ng/mL	Hypoglycemics	LC/TOF-MS
Guaifenesin	LC-MS/MS	0.2 mcg/mL	Guaifenesin	LC/TOF-MS

8042B Confirmation Compound	Confirmation Method	Confirmation Reporting Limit	Compound Class	Screening Method
Haloperidol	LC-MS/MS	1 ng/mL	Haloperidol	LC/TOF-MS
Hydrocodone - Free	LC-MS/MS	5 ng/mL	Opiates - Free (Unconjugated)	LC/TOF-MS
Hydromorphone - Free	LC-MS/MS	1 ng/mL	Opiates - Free (Unconjugated)	LC/TOF-MS
Hydroxybupropion	LC-MS/MS	100 ng/mL	Bupropion and Metabolite	LC/TOF-MS
Hydroxyethylflurazepam	LC-MS/MS	5 ng/mL	Benzodiazepines	LC/TOF-MS
Hydroxytriazolam	LC-MS/MS	5 ng/mL	Benzodiazepines	LC/TOF-MS
Hydroxyzine	LC-MS/MS	5 ng/mL	Hydroxyzine	LC/TOF-MS
Iloperidone	LC-MS/MS	0.25 ng/mL	Iloperidone	LC/TOF-MS
Imipramine	GC	20 ng/mL	Imipramine and Metabolite	LC/TOF-MS
Isobutyrylfentanyl	LC-MS/MS	0.05 ng/mL	Designer Opioids (2018 Scope)	LC/TOF-MS
Isopropanol	Headspace GC	5 mg/dL	Alcohols and Acetone	Headspace GC
Ketamine	GC/MS	40 ng/mL	Ketamine and Metabolite	LC/TOF-MS
LSD	LC-MS/MS	0.1 ng/mL	LSD	LC/TOF-MS
Lacosamide	LC-MS/MS	0.5 mcg/mL	Lacosamide	LC/TOF-MS
Lamotrigine	LC-MS/MS	0.2 mcg/mL	Lamotrigine	LC/TOF-MS
Levetiracetam	LC-MS/MS	1 mcg/mL	Levetiracetam	LC/TOF-MS
Loperamide	LC-MS/MS	5 ng/mL	Loperamide and Metabolite	LC/TOF-MS
Lorazepam	LC-MS/MS	5 ng/mL	Benzodiazepines	LC/TOF-MS
Loxapine	LC-MS/MS	5 ng/mL	Loxapine	LC/TOF-MS
MDA	LC-MS/MS	5 ng/mL	Amphetamines	LC/TOF-MS
MDEA	LC-MS/MS	5 ng/mL	Amphetamines	LC/TOF-MS
MDMA	LC-MS/MS	5 ng/mL	Amphetamines	LC/TOF-MS
Maprotiline	GC	20 ng/mL	Maprotiline	LC/TOF-MS
Memantine	LC-MS/MS	10 ng/mL	Memantine	LC/TOF-MS
Meperidine	GC	0.04 mcg/mL	Meperidine and Metabolite	LC/TOF-MS
Meprobamate	GC/MS	1 mcg/mL	Carisoprodol and Metabolite	LC/TOF-MS
Mescaline	GC	0.04 mcg/mL	Mescaline	LC/TOF-MS
Mesoridazine	GC	200 ng/mL	Thioridazine and Metabolite	LC/TOF-MS
Metaxalone	LC-MS/MS	0.025 mcg/mL	Metaxalone	LC/TOF-MS
Methadone	LC-MS/MS	20 ng/mL	Methadone and Metabolite	LC/TOF-MS
Methamphetamine	LC-MS/MS	5 ng/mL	Amphetamines	LC/TOF-MS
Methanol	Headspace GC	5 mg/dL	Alcohols and Acetone	Headspace GC
Methaqualone	GC/MS	0.1 mcg/mL	Methaqualone	LC/TOF-MS
Methocarbamol	LC-MS/MS	2 mcg/mL	Methocarbamol	LC/TOF-MS
Methoxyacetylfentanyl	LC-MS/MS	0.05 ng/mL	Designer Opioids (2018 Scope)	LC/TOF-MS
Methylphenidate	LC-MS/MS	4 ng/mL	Methylphenidate and Metabolite	LC/TOF-MS
Mexiletine	GC	0.05 mcg/mL	Mexiletine	LC/TOF-MS
Midazolam	LC-MS/MS	5 ng/mL	Benzodiazepines	LC/TOF-MS

8042B Confirmation Compound	Confirmation Method	Confirmation Reporting Limit	Compound Class	Screening Method
Mirtazapine	GC	10 ng/mL	Mirtazapine	LC/TOF-MS
Mitragynine	LC-MS/MS	5 ng/mL	Mitragynine	LC/TOF-MS
Morphine - Free	LC-MS/MS	5 ng/mL	Opiates - Free (Unconjugated)	LC/TOF-MS
N-Desmethylsildenafil	LC-MS/MS	2 ng/mL	Sildenafil and Metabolite	LC/TOF-MS
N-Ethyl Pentylone	LC-MS/MS	10 ng/mL	Substituted Cathinone	LC/TOF-MS
Nalbuphine - Free	LC-MS/MS	0.5 ng/mL	Synthetic Opioids - Free (Unconjugated)	LC/TOF-MS
Naltrexone - Free	LC-MS/MS	0.5 ng/mL	Naltrexone and Metabolite - Free (Unconjugated)	LC/TOF-MS
Naproxen	LC-MS/MS	3 mcg/mL	Naproxen	LC/TOF-MS
Nifedipine	LC-MS/MS	5 ng/mL	Nifedipine	LC/TOF-MS
Norbuprenorphine - Free	LC-MS/MS	0.5 ng/mL	Synthetic Opioids - Free (Unconjugated)	LC/TOF-MS
Norclozapine	LC-MS/MS	20 ng/mL	Clozapine and Metabolite	LC/TOF-MS
Nordiazepam	LC-MS/MS	20 ng/mL	Benzodiazepines	LC/TOF-MS
Norfentanyl	LC-MS/MS	0.2 ng/mL	Fentanyl and Acetyl Fentanyl	LC/TOF-MS
Norflunitrazepam	LC-MS/MS	2 ng/mL	Flunitrazepam and Metabolites	LC/TOF-MS
Norfluoxetine	GC/MS	20 ng/mL	Fluoxetine and Metabolite	LC/TOF-MS
Norketamine	GC/MS	40 ng/mL	Ketamine and Metabolite	LC/TOF-MS
Normeperidine	GC	0.02 mcg/mL	Meperidine and Metabolite	LC/TOF-MS
Norpropoxyphene	GC/MS	0.1 mcg/mL	Propoxyphene and Metabolite	LC/TOF-MS
Norpseudoephedrine	LC-MS/MS	5 ng/mL	Amphetamines	LC/TOF-MS
Nortriptyline	GC	20 ng/mL	Amitriptyline and Metabolite	LC/TOF-MS
O-Desmethyltramadol	LC-MS/MS	20 ng/mL	Tramadol and Metabolite	LC/TOF-MS
O-Desmethylvenlafaxine	LC-MS/MS	20 ng/mL	Venlafaxine and Metabolite	LC/TOF-MS
Olanzapine	LC-MS/MS	3 ng/mL	Olanzapine	LC/TOF-MS
Orphenadrine	GC	100 ng/mL	Orphenadrine	LC/TOF-MS
Oxazepam	LC-MS/MS	20 ng/mL	Benzodiazepines	LC/TOF-MS
Oxycodone - Free	LC-MS/MS	5 ng/mL	Opiates - Free (Unconjugated)	LC/TOF-MS
Oxymorphone - Free	LC-MS/MS	1 ng/mL	Opiates - Free (Unconjugated)	LC/TOF-MS
Paroxetine	LC-MS/MS	10 ng/mL	Paroxetine	LC/TOF-MS
Pentobarbital	GC/MS	0.2 mcg/mL	Barbiturates	ELISA
Perphenazine	LC-MS/MS	0.2 ng/mL	Perphenazine	LC/TOF-MS
Phenazepam	LC-MS/MS	20 ng/mL	Phenazepam	LC/TOF-MS
Phencyclidine	LC-MS/MS	5 ng/mL	Phencyclidine	LC/TOF-MS
Pheniramine	GC	40 ng/mL	Pheniramine	LC/TOF-MS
Phenobarbital	GC/MS	0.5 mcg/mL	Barbiturates	ELISA
Phentermine	LC-MS/MS	5 ng/mL	Amphetamines	LC/TOF-MS
Phenylethylmalonamide (PEMA)	LC-MS/MS	0.5 mcg/mL	Primidonel and PEMA	LC/TOF-MS

8042B Confirmation Compound	Confirmation Method	Confirmation Reporting Limit	Compound Class	Screening Method
Phenylpropanolamine	LC-MS/MS	5 ng/mL	Amphetamines	LC/TOF-MS
Phenytoin	LC-MS/MS	0.5 mcg/mL	Phenytoin	LC/TOF-MS
Primidone	LC-MS/MS	0.5 mcg/mL	Primidone and PEMA	LC/TOF-MS
Prochlorperazine	LC-MS/MS	1 ng/mL	Prochlorperazine	LC/TOF-MS
Promazine	LC-MS/MS	5 ng/mL	Promazine	LC/TOF-MS
Promethazine	LC-MS/MS	5 ng/mL	Promethazine	LC/TOF-MS
Propoxyphene	GC/MS	0.1 mcg/mL	Propoxyphene and Metabolite	LC/TOF-MS
Pseudoephedrine	LC-MS/MS	5 ng/mL	Amphetamines	LC/TOF-MS
Psilocin	LC-MS/MS	10 ng/mL	Psilocin	LC/TOF-MS
Quetiapine	LC-MS/MS	50 ng/mL	Quetiapine	LC/TOF-MS
Quinidine	LC-MS/MS	100 ng/mL	Quinidine	LC/TOF-MS
Risperidone	LC-MS/MS	1 ng/mL	Risperidone and Metabolite	LC/TOF-MS
Risperidone and 9-Hydroxyrisperidone - Total	LC-MS/MS	ng/mL	Risperidone and Metabolite	LC/TOF-MS
Ritalinic Acid	LC-MS/MS	20 ng/mL	Methylphenidate and Metabolite	LC/TOF-MS
Salicylate	LC-MS/MS	5 mcg/mL	Salicylate	ELISA
Salvinorin B	LC-MS/MS	1 ng/mL	Salvinorin B	LC/TOF-MS
Secobarbital	GC/MS	0.2 mcg/mL	Barbiturates	ELISA
Sertraline	LC-MS/MS	10 ng/mL	Sertraline and Desmethylsertraline	LC/TOF-MS
Sildenafil	LC-MS/MS	2 ng/mL	Sildenafil and Metabolite	LC/TOF-MS
Strychnine	GC	20 ng/mL	Strychnine	LC/TOF-MS
Sufentanil	LC-MS/MS	0.1 ng/mL	Alfentanil and Sufentanil	LC/TOF-MS
TFMPP	GC/MS	10 ng/mL	Piperazine Designer Drugs	LC/TOF-MS
Tadalafil	LC-MS/MS	10 ng/mL	Tadalafil	LC/TOF-MS
Tapentadol - Free	LC-MS/MS	5 ng/mL	Tapentadol - Free	LC/TOF-MS
Temazepam	LC-MS/MS	20 ng/mL	Benzodiazepines	LC/TOF-MS
Tetrahydrozoline	LC-MS/MS	0.1 ng/mL	Tetrahydrozoline	LC/TOF-MS
Theophylline	LC-MS/MS	0.5 mcg/mL	Theophylline	LC/TOF-MS
Thioridazine	GC	200 ng/mL	Thioridazine and Metabolite	LC/TOF-MS
Tiletamine	GC	0.05 mcg/mL	Tiletamine	LC/TOF-MS
Topiramate	LC-MS/MS	200 ng/mL	Topiramate	LC/TOF-MS
Tramadol	LC-MS/MS	20 ng/mL	Tramadol and Metabolite	LC/TOF-MS
Trazodone	LC-MS/MS	0.05 mcg/mL	Trazodone and mCPP	LC/TOF-MS
Triazolam	LC-MS/MS	2 ng/mL	Benzodiazepines	LC/TOF-MS
Trifluoperazine	LC-MS/MS	0.2 ng/mL	Trifluoperazine	LC/TOF-MS
Trihexyphenidyl	GC	1 ng/mL	Trihexyphenidyl	LC/TOF-MS
Trimipramine	GC	20 ng/mL	Trimipramine and Metabolite	LC/TOF-MS



8042B Confirmation Compound	Confirmation Method	Confirmation Reporting Limit	Compound Class	Screening Method
Triprolidine	GC	60 ng/mL	Triprolidine	LC/TOF-MS
U-47700	LC-MS/MS	0.05 ng/mL	Designer Opioids (2018 Scope)	LC/TOF-MS
Valeryl Fentanyl	LC-MS/MS	0.05 ng/mL	Designer Opioids (2018 Scope)	LC/TOF-MS
Vardenafil	LC-MS/MS	5 ng/mL	Vardenafil and Metabolite	LC/TOF-MS
Venlafaxine	LC-MS/MS	20 ng/mL	Venlafaxine and Metabolite	LC/TOF-MS
Verapamil	GC	20 ng/mL	Verapamil	LC/TOF-MS
Xylazine	LC-MS/MS	5 ng/mL	Xylazine	LC/TOF-MS
Yohimbine	LC-MS/MS	4 ng/mL	Yohimbine	LC/TOF-MS
Zaleplon	LC-MS/MS	4 ng/mL	Zaleplon	LC/TOF-MS
Ziprasidone	LC-MS/MS	2 ng/mL	Ziprasidone	LC/TOF-MS
Zolazepam	GC	0.05 mcg/mL	Zolazepam	LC/TOF-MS
Zolpidem	LC-MS/MS	4 ng/mL	Zolpidem	LC/TOF-MS
Zonisamide	LC-MS/MS	0.5 mcg/mL	Zonisamide	LC/TOF-MS
cis-3-Methylfentanyl	LC-MS/MS	0.05 ng/mL	Designer Opioids (2018 Scope)	LC/TOF-MS
mCPP	LC-MS/MS	0.05 mcg/mL	Trazodone and mCPP	LC/TOF-MS
para-Fluorobutyrylfentanyl	LC-MS/MS	0.05 ng/mL	Designer Opioids (2018 Scope)	LC/TOF-MS
para-Fluoroisobutyrylfentanyl	LC-MS/MS	0.05 ng/mL	Designer Opioids (2018 Scope)	LC/TOF-MS
trans-3-Methylfentanyl	LC-MS/MS	0.05 ng/mL	Designer Opioids (2018 Scope)	LC/TOF-MS

Acocode	Description	Scope	Test Price
8054B	Postmortem Expanded with NPS Toxicology Panel	Additional 50+ NPS compounds included with the Expanded Panel (8052)	Blood: \$553

8054B Postmortem, Expanded with NPS, Blood scope of testing:

8054B Confirmation Compound	Confirmation Method	Confirmation Reporting Limit	Compound Class	Screening Method
10-Hydroxycarbazepine	LC-MS/MS	0.5 mcg/mL	Oxcarbazepine/Eslicarbazepine Acetate as Metabolite	LC/TOF-MS
11-Hydroxy Delta-9 THC	LC-MS/MS	1 ng/mL	Cannabinoids	ELISA
2-Furanylfentanyl	LC-MS/MS	0.05 ng/mL	Designer Opioids	LC/TOF-MS
25B-NBOMe	LC-MS/MS	0.5 ng/mL	NBOMe	LC/TOF-MS
25C-NBOMe	LC-MS/MS	0.5 ng/mL	NBOMe	LC/TOF-MS
25H-NBOMe	LC-MS/MS	0.5 ng/mL	NBOMe	LC/TOF-MS
25I-NBOMe	LC-MS/MS	0.5 ng/mL	NBOMe	LC/TOF-MS
3-Fluorophenmetrazine	GC/MS	25 ng/mL	Hallucinogens and Stimulants	LC/TOF-MS
3-MeO-PCP	GC/MS	10 ng/mL	Hallucinogens and Stimulants	LC/TOF-MS
4-ANPP	LC-MS/MS	0.1 ng/mL	Designer Opioids	LC/TOF-MS
4-MeO-PCP	GC/MS	10 ng/mL	Hallucinogens and Stimulants	LC/TOF-MS
4-cyano-CUMYL-BINACA	LC-MS/MS	0.1 ng/mL	Synthetic Cannabinoids	LC-MS/MS QTRAP
4-fluoro-MDMB-BINACA	LC-MS/MS	0.1 ng/mL	Synthetic Cannabinoids	LC-MS/MS QTRAP
5-fluoro-EDMB-PINACA	LC-MS/MS	0.1 ng/mL	Synthetic Cannabinoids	LC-MS/MS QTRAP
5-fluoro-MDMB-PICA	LC-MS/MS	0.1 ng/mL	Synthetic Cannabinoids	LC-MS/MS QTRAP
5-fluoro-MDMB-PINACA / 5-fluoro-EMB-PINACA	LC-MS/MS	0.2 ng/mL	Synthetic Cannabinoids	LC-MS/MS QTRAP
5-fluoro-MMB-PINACA	LC-MS/MS	0.05 ng/mL	Synthetic Cannabinoids	LC-MS/MS QTRAP
5-fluoro-NA-PIC	LC-MS/MS	0.1 ng/mL	Synthetic Cannabinoids	LC-MS/MS QTRAP
5-fluoro-QU-PINAC	LC-MS/MS	0.1 ng/mL	Synthetic Cannabinoids	LC-MS/MS QTRAP
6-Beta-Naltrexol - Free	LC-MS/MS	0.5 ng/mL	Naltrexone and Metabolite - Free (Unconjugated)	LC/TOF-MS
6-Monoacetylmorphine - Free	LC-MS/MS	1 ng/mL	Opiates - Free (Unconjugated)	LC/TOF-MS
7-Amino Clonazepam	LC-MS/MS	5 ng/mL	Benzodiazepines	LC/TOF-MS
7-Amino Flunitrazepam	LC-MS/MS	2 ng/mL	Flunitrazepam and Metabolites	LC/TOF-MS
9-Hydroxyrisperidone	LC-MS/MS	1 ng/mL	Risperidone and Metabolite	LC/TOF-MS
ADAMANTYL-FUBINACA	LC-MS/MS	0.2 ng/mL	Synthetic Cannabinoids	LC-MS/MS QTRAP
ADMB-CHMINACA	LC-MS/MS	0.1 ng/mL	Synthetic Cannabinoids	LC-MS/MS QTRAP
ADMB-FUBICA	LC-MS/MS	1 ng/mL	Synthetic Cannabinoids	LC-MS/MS QTRAP

8054B Confirmation Compound	Confirmation Method	Confirmation Reporting Limit	Compound Class	Screening Method
ADMB-FUBINACA	LC-MS/MS	1 ng/mL	Synthetic Cannabinoids	LC-MS/MS QTRAP
AMB-CHMINACA	LC-MS/MS	1 ng/mL	Synthetic Cannabinoids	LC-MS/MS QTRAP
AMB-FUBINACA	LC-MS/MS	1 ng/mL	Synthetic Cannabinoids	LC-MS/MS QTRAP
Acetaminophen	LC-MS/MS	0.5 mcg/mL	Acetaminophen	LC/TOF-MS
Acetone	Headspace GC	5 mg/dL	Alcohols and Acetone	Headspace GC
Acetyl Fentanyl	LC-MS/MS	0.1 ng/mL	Fentanyl and Acetyl Fentanyl	LC/TOF-MS
Acryl Fentanyl	LC-MS/MS	0.05 ng/mL	Designer Opioids	LC/TOF-MS
Alfentanil	LC-MS/MS	0.1 ng/mL	Alfentanil and Sufentanil	LC/TOF-MS
Alpha-Hydroxyalprazolam	LC-MS/MS	5 ng/mL	Benzodiazepines	LC/TOF-MS
Alprazolam	LC-MS/MS	5 ng/mL	Benzodiazepines	LC/TOF-MS
Amitriptyline	GC	20 ng/mL	Amitriptyline and Metabolite	LC/TOF-MS
Amobarbital	GC/MS	0.2 mcg/mL	Barbiturates	ELISA
Amoxapine	LC-MS/MS	10 ng/mL	Amoxapine	LC/TOF-MS
Amphetamine	LC-MS/MS	5 ng/mL	Amphetamines	LC/TOF-MS
Aripiprazole	LC-MS/MS	20 ng/mL	Aripiprazole	LC/TOF-MS
Atomoxetine	GC/MS	20 ng/mL	Atomoxetine	LC/TOF-MS
BZP	GC/MS	10 ng/mL	Piperazine Designer Drugs	LC/TOF-MS
Benzoylcegonine	GC/MS	50 ng/mL	Cocaine and Metabolites	LC/TOF-MS
Benztropine	LC-MS/MS	1 ng/mL	Benztropine	LC/TOF-MS
Bromazepam	LC-MS/MS	5 ng/mL	Designer Benzodiazepines	LC/TOF-MS
Brompheniramine	GC	40 ng/mL	Brompheniramine	LC/TOF-MS
Bupivacaine	GC	0.1 mcg/mL	Bupivacaine	LC/TOF-MS
Buprenorphine - Free	LC-MS/MS	0.5 ng/mL	Synthetic Opioids - Free (Unconjugated)	LC/TOF-MS
Bupropion	LC-MS/MS	10 ng/mL	Bupropion and Metabolite	LC/TOF-MS
Buspirone	LC-MS/MS	0.5 ng/mL	Buspirone	LC/TOF-MS
Butabarbital	GC/MS	0.2 mcg/mL	Barbiturates	ELISA
Butalbital	GC/MS	0.2 mcg/mL	Barbiturates	ELISA
Butorphanol - Free	LC-MS/MS	0.5 ng/mL	Synthetic Opioids - Free (Unconjugated)	LC/TOF-MS
Butylone	LC-MS/MS	10 ng/mL	Substituted Cathinone Panel, Blood	LC/TOF-MS
Butyrylfentanyl	LC-MS/MS	0.05 ng/mL	Designer Opioids	LC/TOF-MS
CUMYL-THPINACA	LC-MS/MS	0.1 ng/mL	Synthetic Cannabinoids	LC-MS/MS QTRAP
Carbamazepine	LC-MS/MS	0.2 mcg/mL	Carbamazepine and Metabolite	LC/TOF-MS
Carbamazepine-10,11-Epoxy	LC-MS/MS	0.2 mcg/mL	Carbamazepine and Metabolite	LC/TOF-MS
Carfentanil	LC-MS/MS	0.05 ng/mL	Designer Opioids	LC/TOF-MS
Carisoprodol	GC/MS	0.2 mcg/mL	Carisoprodol and Metabolite	LC/TOF-MS
Chlordiazepoxide	LC-MS/MS	20 ng/mL	Benzodiazepines	LC/TOF-MS
Chlorpheniramine	LC-MS/MS	10 ng/mL	Chlorpheniramine	LC/TOF-MS

8054B Confirmation Compound	Confirmation Method	Confirmation Reporting Limit	Compound Class	Screening Method
Chlorpromazine	GC	20 ng/mL	Chlorpromazine	LC/TOF-MS
Citalopram / Escitalopram	LC-MS/MS	5 ng/mL	Citalopram	LC/TOF-MS
Clephedrone	GC/MS	50 ng/mL	Hallucinogens and Stimulants	LC/TOF-MS
Clobazam	LC-MS/MS	20 ng/mL	Benzodiazepines	LC/TOF-MS
Clomipramine	GC	20 ng/mL	Clomipramine and Metabolite	LC/TOF-MS
Clonazepam	LC-MS/MS	2 ng/mL	Benzodiazepines	LC/TOF-MS
Clonazepam	LC-MS/MS	5 ng/mL	Designer Benzodiazepines	LC/TOF-MS
Clonidine	LC-MS/MS	0.1 ng/mL	Clonidine	LC/TOF-MS
Clozapine	LC-MS/MS	20 ng/mL	Clozapine and Metabolite	LC/TOF-MS
Cocaeethylene	GC/MS	20 ng/mL	Cocaine and Metabolites	LC/TOF-MS
Cocaine	GC/MS	20 ng/mL	Cocaine and Metabolites	LC/TOF-MS
Codeine - Free	LC-MS/MS	5 ng/mL	Opiates - Free (Unconjugated)	LC/TOF-MS
Cyclobenzaprine	LC-MS/MS	1 ng/mL	Cyclobenzaprine	LC/TOF-MS
Cyclopropylfentanyl	LC-MS/MS	0.05 ng/mL	Designer Opioids	LC/TOF-MS
Delorazepam	LC-MS/MS	5 ng/mL	Designer Benzodiazepines	LC/TOF-MS
Delta-9 Carboxy THC	LC-MS/MS	5 ng/mL	Cannabinoids	ELISA
Delta-9 THC	LC-MS/MS	0.5 ng/mL	Cannabinoids	ELISA
Desalkylflurazepam	LC-MS/MS	5 ng/mL	Benzodiazepines	LC/TOF-MS
Deschloroetizolam	LC-MS/MS	2 ng/mL	Designer Benzodiazepines	LC/TOF-MS
Desethylildenafil	LC-MS/MS	5 ng/mL	Vardenafil and Metabolite	LC/TOF-MS
Desipramine	GC : GCPADO2A	20 ng/mL	Imipramine and Metabolite	LC/TOF-MS
Desmethyldomipramine	GC : GCPADO1A	20 ng/mL	Clomipramine and Metabolite	LC/TOF-MS
Desmethyldoxepin	GC : GCPADO1A	20 ng/mL	Doxepin and Metabolite	LC/TOF-MS
Desmethylloperamide	LC-MS/MS	5 ng/mL	Loperamide and Metabolite	LC/TOF-MS
Desmethylsertraline	LC-MS/MS	20 ng/mL	Sertraline and Desmethylsertraline	LC/TOF-MS
Desmethyltrimipramine	GC : GCPADO2A	20 ng/mL	Trimipramine and Metabolite	LC/TOF-MS
Dextro / Levo Methorphan	LC-MS/MS	5 ng/mL	D/L Methorphan, Dextrorphan & Levorphanol	LC/TOF-MS
Dextrorphan / Levorphanol	LC-MS/MS	2 ng/mL	D/L Methorphan, Dextrorphan & Levorphanol	LC/TOF-MS
Diazepam	LC-MS/MS	20 ng/mL	Benzodiazepines	LC/TOF-MS
Dibutylone	LC-MS/MS	10 ng/mL	Substituted Cathinone Panel, Blood	LC/TOF-MS
Diclazepam	LC-MS/MS	5 ng/mL	Designer Benzodiazepines	LC/TOF-MS
Dicyclomine	LC-MS/MS	1 ng/mL	Dicyclomine	LC/TOF-MS
Dihydrocodeine / Hydrocodol - Free	LC-MS/MS	5 ng/mL	Opiates - Free (Unconjugated)	LC/TOF-MS
Diltiazem	LC-MS/MS	5 ng/mL	Diltiazem	LC/TOF-MS
Diphenhydramine	LC-MS/MS	50 ng/mL	Diphenhydramine	LC/TOF-MS
Donepezil	LC-MS/MS	5 ng/mL	Donepezil	LC/TOF-MS
Doxepin	GC : GCPADO1A	20 ng/mL	Doxepin and Metabolite	LC/TOF-MS

8054B Confirmation Compound	Confirmation Method	Confirmation Reporting Limit	Compound Class	Screening Method
Doxylamine	GC	100 ng/mL	Doxylamine	LC/TOF-MS
Duloxetine	LC-MS/MS	30 ng/mL	Duloxetine	LC/TOF-MS
EDDP	LC-MS/MS	20 ng/mL	Methadone and Metabolite	LC/TOF-MS
Ephedrine	LC-MS/MS	5 ng/mL	Amphetamines	LC/TOF-MS
Estazolam	LC-MS/MS	5 ng/mL	Benzodiazepines	LC/TOF-MS
Eszopiclone / Zopiclone	LC-MS/MS	2 ng/mL	Eszopiclone / Zopiclone	LC/TOF-MS
Ethanol	Headspace GC	10 mg/dL	Alcohols and Acetone	Headspace GC
Ethylone	LC-MS/MS	10 ng/mL	Substituted Cathinone Panel, Blood	LC/TOF-MS
Etizolam	LC-MS/MS	2 ng/mL	Designer Benzodiazepines	LC/TOF-MS
Fentanyl	LC-MS/MS	0.1 ng/mL	Fentanyl and Acetyl Fentanyl	LC/TOF-MS
Flecainide	LC-MS/MS	0.05 mcg/mL	Flecainide	LC/TOF-MS
Flubromazepam	LC-MS/MS	20 ng/mL	Designer Benzodiazepines	LC/TOF-MS
Flubromazolam	LC-MS/MS	2 ng/mL	Designer Benzodiazepines	LC/TOF-MS
Flunitrazepam	LC-MS/MS	2 ng/mL	Flunitrazepam and Metabolites	LC/TOF-MS
Fluoxetine	GC/MS	20 ng/mL	Fluoxetine and Metabolite	LC/TOF-MS
Fluphenazine	LC-MS/MS	0.5 ng/mL	Fluphenazine	LC/TOF-MS
Flurazepam	LC-MS/MS	2 ng/mL	Benzodiazepines	LC/TOF-MS
Fluvoxamine	GC	10 ng/mL	Fluvoxamine	LC/TOF-MS
Gabapentin	LC-MS/MS	1 mcg/mL	Gabapentin	ELISA
Glimepiride	LC-MS/MS	25 ng/mL	Glimepiride	LC/TOF-MS
Glipizide	LC-MS/MS	40 ng/mL	Hypoglycemics	LC/TOF-MS
Glyburide	LC-MS/MS	40 ng/mL	Hypoglycemics	LC/TOF-MS
Guaifenesin	LC-MS/MS	0.2 mcg/mL	Guaifenesin	LC/TOF-MS
Haloperidol	LC-MS/MS	1 ng/mL	Haloperidol	LC/TOF-MS
Hydrocodone - Free	LC-MS/MS	5 ng/mL	Opiates - Free (Unconjugated)	LC/TOF-MS
Hydromorphone - Free	LC-MS/MS	1 ng/mL	Opiates - Free (Unconjugated)	LC/TOF-MS
Hydroxybupropion	LC-MS/MS	100 ng/mL	Bupropion and Metabolite	LC/TOF-MS
Hydroxyethylflurazepam	LC-MS/MS	5 ng/mL	Benzodiazepines	LC/TOF-MS
Hydroxytriazolam	LC-MS/MS	5 ng/mL	Benzodiazepines	LC/TOF-MS
Hydroxyzine	LC-MS/MS	5 ng/mL	Hydroxyzine	LC/TOF-MS
Iloperidone	LC-MS/MS	0.25 ng/mL	Iloperidone	LC/TOF-MS
Imipramine	GC	20 ng/mL	Imipramine and Metabolite	LC/TOF-MS
Isobutyrylfentanyl	LC-MS/MS	0.05 ng/mL	Designer Opioids	LC/TOF-MS
Isopropanol	Headspace GC	5 mg/dL	Alcohols and Acetone	Headspace GC
Ketamine	GC/MS	40 ng/mL	Ketamine and Metabolite	LC/TOF-MS
LSD	LC-MS/MS	0.1 ng/mL	LSD	LC/TOF-MS
Lacosamide	LC-MS/MS	0.5 mcg/mL	Lacosamide	LC/TOF-MS
Lamotrigine	LC-MS/MS	0.2 mcg/mL	Lamotrigine	LC/TOF-MS

8054B Confirmation Compound	Confirmation Method	Confirmation Reporting Limit	Compound Class	Screening Method
Levetiracetam	LC-MS/MS	1 mcg/mL	Levetiracetam	LC/TOF-MS
Loperamide	LC-MS/MS	5 ng/mL	Loperamide and Metabolite	LC/TOF-MS
Lorazepam	LC-MS/MS	5 ng/mL	Benzodiazepines	LC/TOF-MS
Loxapine	LC-MS/MS	5 ng/mL	Loxapine	LC/TOF-MS
MDA	LC-MS/MS	5 ng/mL	Amphetamines	LC/TOF-MS
MDEA	LC-MS/MS	5 ng/mL	Amphetamines	LC/TOF-MS
MDMA	LC-MS/MS	5 ng/mL	Amphetamines	LC/TOF-MS
MDMB-CHMCZCA	LC-MS/MS	0.1 ng/mL	Synthetic Cannabinoids	LC-MS/MS QTRAP
MDMB-CHMICA	LC-MS/MS	0.1 ng/mL	Synthetic Cannabinoids	LC-MS/MS QTRAP
MDMB-CHMINAC	LC-MS/MS	0.1 ng/mL	Synthetic Cannabinoids	LC-MS/MS QTRAP
MDMB-FUBICA	LC-MS/MS	0.1 ng/mL	Synthetic Cannabinoids	LC-MS/MS QTRAP
MDMB-FUBINACA / EMB-FUBINACA	LC-MS/MS	0.1 ng/mL	Synthetic Cannabinoids	LC-MS/MS QTRAP
MDPV	LC-MS/MS	10 ng/mL	Bath Salts	LC/TOF-MS
MMB-CHMICA	LC-MS/MS	0.1 ng/mL	Synthetic Cannabinoids	LC-MS/MS QTRAP
MMB-CHMINACA	LC-MS/MS	0.2 ng/mL	Synthetic Cannabinoids	LC-MS/MS QTRAP
MMB-FUBICA	LC-MS/MS	1 ng/mL	Synthetic Cannabinoids	LC-MS/MS QTRAP
MMB-FUBINACA	LC-MS/MS	0.1 ng/mL	Synthetic Cannabinoids	LC-MS/MS QTRAP
MPHP	LC-MS/MS	5 ng/mL	Pyrrolidinophenone	LC/TOF-MS
Maprotiline	GC	20 ng/mL	Maprotiline	LC/TOF-MS
Meclonazepam	LC-MS/MS	5 ng/mL	Designer Benzodiazepines	LC/TOF-MS
Memantine	LC-MS/MS	10 ng/mL	Memantine	LC/TOF-MS
Meperidine	GC	0.04 mcg/mL	Meperidine and Metabolite	LC/TOF-MS
Mephedrone	LC-MS/MS	10 ng/mL	Bath Salts	LC/TOF-MS
Meprobamate	GC/MS	1 mcg/mL	Carisoprodol and Metabolite	LC/TOF-MS
Mescaline	GC	0.04 mcg/mL	Mescaline	LC/TOF-MS
Mesoridazine	GC	200 ng/mL	Thioridazine and Metabolite	LC/TOF-MS
Metaxalone	LC-MS/MS	0.025 mcg/mL	Metaxalone	LC/TOF-MS
Methadone	LC-MS/MS	20 ng/mL	Methadone and Metabolite	LC/TOF-MS
Methamphetamine	LC-MS/MS	5 ng/mL	Amphetamines	LC/TOF-MS
Methanol	Headspace GC	5 mg/dL	Alcohols and Acetone	Headspace GC
Methaqualone	GC/MS	0.1 mcg/mL	Methaqualone	LC/TOF-MS
Methcathinone	LC-MS/MS	10 ng/mL	Methcathinone	LC/TOF-MS
Methocarbamol	LC-MS/MS	2 mcg/mL	Methocarbamol	LC/TOF-MS
Methoxetamine	LC-MS/MS	2 ng/mL	Bath Salts	LC/TOF-MS
Methoxphenidine	GC/MS	5 ng/mL	Hallucinogens and Stimulants	LC/TOF-MS
Methoxyacetylfentanyl	LC-MS/MS	0.05 ng/mL	Designer Opioids	LC/TOF-MS
Methylone	LC-MS/MS	5 ng/mL	Bath Salts	LC/TOF-MS

8054B Confirmation Compound	Confirmation Method	Confirmation Reporting Limit	Compound Class	Screening Method
Methylphenidate	LC-MS/MS	4 ng/mL	Methylphenidate and Metabolite	LC/TOF-MS
Mexiletine	GC	0.05 mcg/mL	Mexiletine	LC/TOF-MS
Midazolam	LC-MS/MS	5 ng/mL	Benzodiazepines	LC/TOF-MS
Mirtazapine	GC	10 ng/mL	Mirtazapine	LC/TOF-MS
Mitragynine	LC-MS/MS	5 ng/mL	Mitragynine	LC/TOF-MS
Morphine - Free	LC-MS/MS	5 ng/mL	Opiates - Free (Unconjugated)	LC/TOF-MS
N-Desmethylsildenafil	LC-MS/MS	2 ng/mL	Sildenafil and Metabolite	LC/TOF-MS
N-Ethyl Pentylone	LC-MS/MS	10 ng/mL	Substituted Cathinone Panel, Blood	LC/TOF-MS
NA-FUBIC	LC-MS/MS	1 ng/mL	Synthetic Cannabinoids	LC-MS/MS QTRAP
NA-FUBIM	LC-MS/MS	0.1 ng/mL	Synthetic Cannabinoids	LC-MS/MS QTRAP
Nalbuphine - Free	LC-MS/MS	0.5 ng/mL	Synthetic Opioids - Free (Unconjugated)	LC/TOF-MS
Naltrexone - Free	LC-MS/MS	0.5 ng/mL	Naltrexone and Metabolite - Free (Unconjugated)	LC/TOF-MS
Naproxen	LC-MS/MS	3 mcg/mL	Naproxen	LC/TOF-MS
Nifedipine	LC-MS/MS	5 ng/mL	Nifedipine	LC/TOF-MS
Norbuprenorphine - Free	LC-MS/MS	0.5 ng/mL	Synthetic Opioids - Free (Unconjugated)	LC/TOF-MS
Norclozapine	LC-MS/MS	20 ng/mL	Clozapine and Metabolite	LC/TOF-MS
Nordiazepam	LC-MS/MS	20 ng/mL	Benzodiazepines	LC/TOF-MS
Norfentanyl	LC-MS/MS	0.2 ng/mL	Fentanyl and Acetyl Fentanyl	LC/TOF-MS
Norflunitrazepam	LC-MS/MS	2 ng/mL	Flunitrazepam and Metabolites	LC/TOF-MS
Norfluoxetine	GC/MS	20 ng/mL	Fluoxetine and Metabolite	LC/TOF-MS
Norketamine	GC/MS	40 ng/mL	Ketamine and Metabolite	LC/TOF-MS
Normeperidine	GC	0.02 mcg/mL	Meperidine and Metabolite	LC/TOF-MS
Norpropoxyphene	GC/MS	0.1 mcg/mL	Propoxyphene and Metabolite	LC/TOF-MS
Norpseudoephedrine	LC-MS/MS	5 ng/mL	Amphetamines	LC/TOF-MS
Nortriptyline	GC	20 ng/mL	Amitriptyline and Metabolite	LC/TOF-MS
O-Desmethyltramadol	LC-MS/MS	20 ng/mL	Tramadol and Metabolite	LC/TOF-MS
O-Desmethylvenlafaxine	LC-MS/MS	20 ng/mL	Venlafaxine and Metabolite	LC/TOF-MS
Olanzapine	LC-MS/MS	3 ng/mL	Olanzapine	LC/TOF-MS
Orphenadrine	GC	100 ng/mL	Orphenadrine	LC/TOF-MS
Oxazepam	LC-MS/MS	20 ng/mL	Benzodiazepines	LC/TOF-MS
Oxycodone - Free	LC-MS/MS	5 ng/mL	Opiates - Free (Unconjugated)	LC/TOF-MS
Oxymorphone - Free	LC-MS/MS	1 ng/mL	Opiates - Free (Unconjugated)	LC/TOF-MS
PMA	LC-MS/MS	10 ng/mL	PMA	LC/TOF-MS
Paroxetine	LC-MS/MS	10 ng/mL	Paroxetine	LC/TOF-MS
Pentedrone	LC-MS/MS	2 ng/mL	Bath Salts	LC/TOF-MS
Pentobarbital	GC/MS	0.2 mcg/mL	Barbiturates	ELISA
Pentylone	LC-MS/MS	10 ng/mL	Substituted Cathinone Panel, Blood	LC/TOF-MS

8054B Confirmation Compound	Confirmation Method	Confirmation Reporting Limit	Compound Class	Screening Method
Perphenazine	LC-MS/MS	0.2 ng/mL	Perphenazine	LC/TOF-MS
Phenazepam	LC-MS/MS	20 ng/mL	Designer Benzodiazepines	LC/TOF-MS
Phencyclidine	LC-MS/MS	5 ng/mL	Phencyclidine	LC/TOF-MS
Pheniramine	GC	40 ng/mL	Pheniramine	LC/TOF-MS
Phenobarbital	GC/MS	0.5 mcg/mL	Barbiturates	ELISA
Phentermine	LC-MS/MS	5 ng/mL	Amphetamines	LC/TOF-MS
Phenylethylmalonamide (PEMA)	LC-MS/MS	0.5 mcg/mL	Primidone and PEMA	LC/TOF-MS
Phenylpropanolamine	LC-MS/MS	5 ng/mL	Amphetamines	LC/TOF-MS
Phenytoin	LC-MS/MS	0.5 mcg/mL	Phenytoin	LC/TOF-MS
Primidone	LC-MS/MS	0.5 mcg/mL	Primidone and PEMA	LC/TOF-MS
Prochlorperazine	LC-MS/MS	1 ng/mL	Prochlorperazine	LC/TOF-MS
Promazine	LC-MS/MS	5 ng/mL	Promazine	LC/TOF-MS
Promethazine	LC-MS/MS	5 ng/mL	Promethazine	LC/TOF-MS
Propoxyphene	GC/MS	0.1 mcg/mL	Propoxyphene and Metabolite	LC/TOF-MS
Pseudoephedrine	LC-MS/MS	5 ng/mL	Amphetamines	LC/TOF-MS
Psilocin	LC-MS/MS	10 ng/mL	Psilocin	LC/TOF-MS
Pyrazolam	LC-MS/MS	5 ng/mL	Designer Benzodiazepines	LC/TOF-MS
Quetiapine	LC-MS/MS	50 ng/mL	Quetiapine	LC/TOF-MS
Quinidine	LC-MS/MS	100 ng/mL	Quinidine	LC/TOF-MS
Risperidone	LC-MS/MS	1 ng/mL	Risperidone and Metabolite	LC/TOF-MS
Risperidone and 9-Hydroxyrisperidone - Total	LC-MS/MS	ng/mL	Risperidone and Metabolite	LC/TOF-MS
Ritalinic Acid	LC-MS/MS	20 ng/mL	Methylphenidate and Metabolite	LC/TOF-MS
Salicylate	LC-MS/MS	5 mcg/mL	Salicylate	ELISA
Secobarbital	GC/MS	0.2 mcg/mL	Barbiturates	ELISA
Sertraline	LC-MS/MS	10 ng/mL	Sertraline and Desmethylsertraline	LC/TOF-MS
Sildenafil	LC-MS/MS	2 ng/mL	Sildenafil and Metabolite	LC/TOF-MS
Strychnine	GC & GC/MS	20 ng/mL	Strychnine	LC/TOF-MS
Sufentanil	LC-MS/MS	0.1 ng/mL	Alfentanil and Sufentanil	LC/TOF-MS
TFMPP	GC/MS	10 ng/mL	Piperazine Designer Drugs	LC/TOF-MS
THF-F	LC-MS/MS	0.05 ng/mL	Designer Opioids	LC/TOF-MS
Tadalafil	LC-MS/MS	10 ng/mL	Tadalafil	LC/TOF-MS
Tapentadol - Free	LC-MS/MS	5 ng/mL	Tapentadol - Free	LC/TOF-MS
Temazepam	LC-MS/MS	20 ng/mL	Benzodiazepines	LC/TOF-MS
Tetrahydrozoline	LC-MS/MS	0.1 ng/mL	Tetrahydrozoline	LC/TOF-MS
Theophylline	LC-MS/MS	0.5 mcg/mL	Theophylline	LC/TOF-MS
Thioridazine	GC	200 ng/mL	Thioridazine and Metabolite	LC/TOF-MS



8054B Confirmation Compound	Confirmation Method	Confirmation Reporting Limit	Compound Class	Screening Method
Tiletamine	GC	0.05 mcg/mL	Tiletamine	LC/TOF-MS
Topiramate	LC-MS/MS	200 ng/mL	Topiramate	LC/TOF-MS
Tramadol	LC-MS/MS	20 ng/mL	Tramadol and Metabolite	LC/TOF-MS
Trazodone	LC-MS/MS	0.05 mcg/mL	Trazodone and mCPP	LC/TOF-MS
Triazolam	LC-MS/MS	2 ng/mL	Benzodiazepines	LC/TOF-MS
Trifluoperazine	LC-MS/MS	0.2 ng/mL	Trifluoperazine	LC/TOF-MS
Trihexyphenidyl	GC	1 ng/mL	Trihexyphenidyl	LC/TOF-MS
Trimipramine	GC	20 ng/mL	Trimipramine and Metabolite	LC/TOF-MS
Tripolidine	GC	60 ng/mL	Tripolidine	LC/TOF-MS
U-47700	LC-MS/MS	0.05 ng/mL	Designer Opioids	LC/TOF-MS
U-49900	LC-MS/MS	0.05 ng/mL	Designer Opioids	LC/TOF-MS
U-51754	LC-MS/MS	0.05 ng/mL	Designer Opioids	LC/TOF-MS
Valeryl Fentanyl	LC-MS/MS	0.05 ng/mL	Designer Opioids	LC/TOF-MS
Vardenafil	LC-MS/MS	5 ng/mL	Vardenafil and Metabolite	LC/TOF-MS
Venlafaxine	LC-MS/MS	20 ng/mL	Venlafaxine and Metabolite	LC/TOF-MS
Verapamil	GC	20 ng/mL	Verapamil	LC/TOF-MS
Xylazine	LC-MS/MS	5 ng/mL	Xylazine	LC/TOF-MS
Yohimbine	LC-MS/MS	4 ng/mL	Yohimbine	LC/TOF-MS
Zaleplon	LC-MS/MS	4 ng/mL	Zaleplon	LC/TOF-MS
Ziprasidone	LC-MS/MS	2 ng/mL	Ziprasidone	LC/TOF-MS
Zolazepam	GC	0.05 mcg/mL	Zolazepam	LC/TOF-MS
Zolpidem	LC-MS/MS	4 ng/mL	Zolpidem	LC/TOF-MS
Zonisamide	LC-MS/MS	0.5 mcg/mL	Zonisamide	LC/TOF-MS
alpha-PVP	LC-MS/MS	2 ng/mL	Bath Salts	LC/TOF-MS
cis-3-Methylfentanyl	LC-MS/MS	0.05 ng/mL	Designer Opioids	LC/TOF-MS
mCPP	LC-MS/MS	0.05 mcg/mL	Trazodone and mCPP	LC/TOF-MS
meta-Methylmethoxyacetylfentanyl	LC-MS/MS	0.05 ng/mL	Designer Opioids	LC/TOF-MS
ortho-Fluorofentanyl	LC-MS/MS	0.05 ng/mL	Designer Opioids	LC/TOF-MS
para-Fluorobutyrylfentanyl	LC-MS/MS	0.05 ng/mL	Designer Opioids	LC/TOF-MS
para-Fluorofentanyl	LC-MS/MS	0.05 ng/mL	Designer Opioids	LC/TOF-MS
para-Fluoroisobutyrylfentanyl	LC-MS/MS	0.05 ng/mL	Designer Opioids	LC/TOF-MS
para-Methylmethoxyacetylfentanyl	LC-MS/MS	0.05 ng/mL	Designer Opioids	LC/TOF-MS
trans-3-Methylfentanyl	LC-MS/MS	0.05 ng/mL	Designer Opioids	LC/TOF-MS

Acode	Description	Scope	Test Price
9566B	Synthetic Cannabinoids, Blood, Panel	Panel currently includes 26 compounds and is updated regularly as additional compounds are discovered.	Blood: \$165

9566B Synthetic Cannabinoids Screen (2019 Scope), Blood scope of testing:

Confirmation Compound	Confirmation Method	Confirmation Reporting Limit	Compound Class	Screening Method
4-cyano-CUMYL-BINACA	LC-MS/MS	0.1 ng/mL	Synthetic Cannabinoids	LC-MS/MS QTRAP
4-fluoro-MDMB-BINACA	LC-MS/MS	0.1 ng/mL	Synthetic Cannabinoids	LC-MS/MS QTRAP
5-fluoro-EDMB-PINACA	LC-MS/MS	0.1 ng/mL	Synthetic Cannabinoids	LC-MS/MS QTRAP
5-fluoro-MDMB-PICA	LC-MS/MS	0.1 ng/mL	Synthetic Cannabinoids	LC-MS/MS QTRAP
5-fluoro-MDMB-PINACA / 5-fluoro-EMB-PINACA	LC-MS/MS	0.2 ng/mL	Synthetic Cannabinoids	LC-MS/MS QTRAP
5-fluoro-MMB-PINACA	LC-MS/MS	0.05 ng/mL	Synthetic Cannabinoids	LC-MS/MS QTRAP
5-fluoro-NA-PIC	LC-MS/MS	0.1 ng/mL	Synthetic Cannabinoids	LC-MS/MS QTRAP
5-fluoro-QU-PINAC	LC-MS/MS	0.1 ng/mL	Synthetic Cannabinoids	LC-MS/MS QTRAP
ADAMANTYL-FUBINACA	LC-MS/MS	0.2 ng/mL	Synthetic Cannabinoids	LC-MS/MS QTRAP
ADMB-CHMINACA	LC-MS/MS	0.1 ng/mL	Synthetic Cannabinoids	LC-MS/MS QTRAP
ADMB-FUBICA	LC-MS/MS	1 ng/mL	Synthetic Cannabinoids	LC-MS/MS QTRAP
ADMB-FUBINACA	LC-MS/MS	1 ng/mL	Synthetic Cannabinoids	LC-MS/MS QTRAP
AMB-CHMINACA	LC-MS/MS	1 ng/mL	Synthetic Cannabinoids	LC-MS/MS QTRAP
AMB-FUBINACA	LC-MS/MS	1 ng/mL	Synthetic Cannabinoids	LC-MS/MS QTRAP
CUMYL-THPINACA	LC-MS/MS	0.1 ng/mL	Synthetic Cannabinoids	LC-MS/MS QTRAP
MDMB-CHMCZCA	LC-MS/MS	0.1 ng/mL	Synthetic Cannabinoids	LC-MS/MS QTRAP
MDMB-CHMICA	LC-MS/MS	0.1 ng/mL	Synthetic Cannabinoids	LC-MS/MS QTRAP
MDMB-CHMINAC	LC-MS/MS	0.1 ng/mL	Synthetic Cannabinoids	LC-MS/MS QTRAP
MDMB-FUBICA	LC-MS/MS	0.1 ng/mL	Synthetic Cannabinoids	LC-MS/MS QTRAP
MDMB-FUBINACA / EMB-FUBINACA	LC-MS/MS	0.1 ng/mL	Synthetic Cannabinoids	LC-MS/MS QTRAP
MMB-CHMICA	LC-MS/MS	0.1 ng/mL	Synthetic Cannabinoids	LC-MS/MS QTRAP
MMB-CHMINACA	LC-MS/MS	0.2 ng/mL	Synthetic Cannabinoids	LC-MS/MS QTRAP
MMB-FUBICA	LC-MS/MS	1 ng/mL	Synthetic Cannabinoids	LC-MS/MS QTRAP
MMB-FUBINACA	LC-MS/MS	0.1 ng/mL	Synthetic Cannabinoids	LC-MS/MS QTRAP
NA-FUBIC	LC-MS/MS	1 ng/mL	Synthetic Cannabinoids	LC-MS/MS QTRAP
NA-FUBIM	LC-MS/MS	0.1 ng/mL	Synthetic Cannabinoids	LC-MS/MS QTRAP

Acode	Description	Scope	Test Price
8155B	Designer Opioids Panel (add-on)	Panel currently includes 21 compounds and is updated regularly as additional compounds are discovered. Urine panel is qualitative.	Blood: \$155 Serum/Plasma: \$155 Urine: \$155

8155B Designer Opioids (2018 Scope), Blood scope of testing:

Screening Compound	Method	Reporting Limit
2-Furanylfentanyl	LC-MS/MS	0.05 ng/mL
4-ANPP	LC-MS/MS	0.1 ng/mL
Acryl Fentanyl	LC-MS/MS	0.05 ng/mL
Butyrylfentanyl	LC-MS/MS	0.05 ng/mL
Carfentanil	LC-MS/MS	0.05 ng/mL
Cyclopropylfentanyl	LC-MS/MS	0.05 ng/mL
Isobutyrylfentanyl	LC-MS/MS	0.05 ng/mL
Methoxyacetylfentanyl	LC-MS/MS	0.05 ng/mL
THF-F	LC-MS/MS	0.05 ng/mL
U-47700	LC-MS/MS	0.05 ng/mL
U-49900	LC-MS/MS	0.05 ng/mL
U-51754	LC-MS/MS	0.05 ng/mL
Valeryl Fentanyl	LC-MS/MS	0.05 ng/mL
cis-3-Methylfentanyl	LC-MS/MS	0.05 ng/mL
meta-Methylmethoxyacetylfentanyl	LC-MS/MS	0.05 ng/mL
ortho-Fluorofentanyl	LC-MS/MS	0.05 ng/mL
para-Fluorobutyrylfentanyl	LC-MS/MS	0.05 ng/mL
para-Fluorofentanyl	LC-MS/MS	0.05 ng/mL
para-Fluoroisobutyrylfentanyl	LC-MS/MS	0.05 ng/mL
para-Methylmethoxyacetylfentanyl	LC-MS/MS	0.05 ng/mL
trans-3-Methylfentanyl	LC-MS/MS	0.05 ng/mL

Accode	Description	Scope	Test Price
8756	Novel Psychoactive Substances (NPS) Screen 1 Panel	Over 50 of the most relevant novel psychoactive substance compounds.	Blood: \$258 Serum/Plasma: \$258 Urine: \$258

8756B Novel Psychoactive Substances (NPS) Screen 1, Blood scope of testing:

8756B Confirmation Compound	Confirmation Method	Confirmation Reporting Limit	Compound Class	Screening Method
25B-NBOMe	LC-MS/MS	0.5 ng/mL	NBOMe	LC/TOF-MS
25C-NBOMe	LC-MS/MS	0.5 ng/mL	NBOMe	LC/TOF-MS
25H-NBOMe	LC-MS/MS	0.5 ng/mL	NBOMe	LC/TOF-MS
25I-NBOMe	LC-MS/MS	0.5 ng/mL	NBOMe	LC/TOF-MS
2-Furanylfentanyl	LC-MS/MS	0.05 ng/mL	Designer Opioids	LC/TOF-MS
3-Fluorophenmetrazine	GC/MS	25 ng/mL	Hallucinogens and Stimulants	LC/TOF-MS
3-MeO-PCP	GC/MS	10 ng/mL	Hallucinogens and Stimulants	LC/TOF-MS
4-ANPP	LC-MS/MS	0.1 ng/mL	Designer Opioids	LC/TOF-MS
4-MeO-PCP	GC/MS	10 ng/mL	Hallucinogens and Stimulants	LC/TOF-MS
Acetyl Fentanyl	LC-MS/MS	0.1 ng/mL	Acetyl Fentanyl	LC/TOF-MS
Acryl Fentanyl	LC-MS/MS	0.05 ng/mL	Designer Opioids	LC/TOF-MS
alpha-PVP	LC-MS/MS	2 ng/mL	Bath Salts	LC/TOF-MS
Bromazepam	LC-MS/MS	5 ng/mL	Designer Benzodiazepines	LC/TOF-MS
Butylone	LC-MS/MS	10 ng/mL	Substituted Cathinone Panel, Blood	LC/TOF-MS
Butyrylfentanyl	LC-MS/MS	0.05 ng/mL	Designer Opioids	LC/TOF-MS
BZP	GC/MS	10 ng/mL	Piperazine Designer Drugs	LC/TOF-MS
Carfentanil	LC-MS/MS	0.05 ng/mL	Designer Opioids	LC/TOF-MS
cis-3-Methylfentanyl	LC-MS/MS	0.05 ng/mL	Designer Opioids	LC/TOF-MS
Clephedrone	GC/MS	50 ng/mL	Hallucinogens and Stimulants	LC/TOF-MS
Clonazepam	LC-MS/MS	5 ng/mL	Designer Benzodiazepines	LC/TOF-MS
Cyclopropylfentanyl	LC-MS/MS	0.05 ng/mL	Designer Opioids	LC/TOF-MS
Delorazepam	LC-MS/MS	5 ng/mL	Designer Benzodiazepines	LC/TOF-MS
Deschloroetizolam	LC-MS/MS	2 ng/mL	Designer Benzodiazepines	LC/TOF-MS
Dibutylone	LC-MS/MS	10 ng/mL	Substituted Cathinone Panel, Blood	LC/TOF-MS
Diclozepam	LC-MS/MS	5 ng/mL	Designer Benzodiazepines	LC/TOF-MS
Ethylone	LC-MS/MS	10 ng/mL	Substituted Cathinone Panel, Blood	LC/TOF-MS
Etizolam	LC-MS/MS	2 ng/mL	Designer Benzodiazepines	LC/TOF-MS
Flubromazepam	LC-MS/MS	20 ng/mL	Designer Benzodiazepines	LC/TOF-MS
Flubromazolam	LC-MS/MS	2 ng/mL	Designer Benzodiazepines	LC/TOF-MS

8756B Confirmation Compound	Confirmation Method	Confirmation Reporting Limit	Compound Class	Screening Method
Isobutyrylfentanyl	LC-MS/MS	0.05 ng/mL	Designer Opioids	LC/TOF-MS
MDPV	LC-MS/MS	10 ng/mL	Bath Salts	LC/TOF-MS
Meclonazepam	LC-MS/MS	5 ng/mL	Designer Benzodiazepines	LC/TOF-MS
Mephedrone	LC-MS/MS	10 ng/mL	Bath Salts	LC/TOF-MS
meta-Methylmethoxyacetylfentanyl	LC-MS/MS	0.05 ng/mL	Designer Opioids	LC/TOF-MS
Methoxetamine	LC-MS/MS	2 ng/mL	Bath Salts	LC/TOF-MS
Methoxphenidine	GC/MS	5 ng/mL	Hallucinogens and Stimulants	LC/TOF-MS
Methoxyacetylfentanyl	LC-MS/MS	0.05 ng/mL	Designer Opioids	LC/TOF-MS
Methylone	LC-MS/MS	5 ng/mL	Bath Salts	LC/TOF-MS
Mitragynine	LC-MS/MS	5 ng/mL	Mitragynine	LC/TOF-MS
MPHP	LC-MS/MS	5 ng/mL	Pyrrolidinophenone	LC/TOF-MS
N-Ethyl Pentylone	LC-MS/MS	10 ng/mL	Substituted Cathinone Panel, Blood	LC/TOF-MS
ortho-Fluorofentanyl	LC-MS/MS	0.05 ng/mL	Designer Opioids	LC/TOF-MS
para-Fluorobutyrylfentanyl	LC-MS/MS	0.05 ng/mL	Designer Opioids	LC/TOF-MS
para-Fluorofentanyl	LC-MS/MS	0.05 ng/mL	Designer Opioids	LC/TOF-MS
para-Fluoroisobutyrylfentanyl	LC-MS/MS	0.05 ng/mL	Designer Opioids	LC/TOF-MS
para-Methylmethoxyacetylfentanyl	LC-MS/MS	0.05 ng/mL	Designer Opioids	LC/TOF-MS
Pentedrone	LC-MS/MS	2 ng/mL	Bath Salts	LC/TOF-MS
Pentylone	LC-MS/MS	10 ng/mL	Substituted Cathinone Panel, Blood	LC/TOF-MS
Phenazepam	LC-MS/MS	20 ng/mL	Designer Benzodiazepines	LC/TOF-MS
Pyrazolam	LC-MS/MS	5 ng/mL	Designer Benzodiazepines	LC/TOF-MS
TFMPP	GC/MS	10 ng/mL	Piperazine Designer Drugs	LC/TOF-MS
THF-F	LC-MS/MS	0.05 ng/mL	Designer Opioids	LC/TOF-MS
trans-3-Methylfentanyl	LC-MS/MS	0.05 ng/mL	Designer Opioids	LC/TOF-MS
U-47700	LC-MS/MS	0.05 ng/mL	Designer Opioids	LC/TOF-MS
U-49900	LC-MS/MS	0.05 ng/mL	Designer Opioids	LC/TOF-MS
U-51754	LC-MS/MS	0.05 ng/mL	Designer Opioids	LC/TOF-MS
Valeryl Fentanyl	LC-MS/MS	0.05 ng/mL	Designer Opioids	LC/TOF-MS

Acode	Description	Scope	Test Price
8050U	Postmortem, Urine Screen Add-on (6-MAM Quantification only)	Includes screening analysis of urine for illicit drugs of abuse with confirmation testing 6-MAM. (Can be ordered in addition to Basic or Expanded Blood drug screens.)	Urine: \$0

805U Postmortem, Urine Screen Add-on (6-MAM Quantification only), Urine scope of testing:

Screening Compound	Method	Reporting Limit
Amphetamines	EIA	500 ng/mL
Barbiturates	EIA	0.3 mcg/mL
Benzodiazepines	EIA	50 ng/mL
Cannabinoids	EIA	50 ng/mL
Cocaine / Metabolites	EIA	150 ng/mL
Fentanyl / Metabolite	EIA	2 ng/mL
Methadone / Metabolite	EIA	300 ng/mL
Opiates	EIA	300 ng/mL
Oxycodone / Oxymorphone	EIA	100 ng/mL
Phencyclidine	EIA	25 ng/mL

Acode	Description	Scope	Test Price
1919FL	Electrolytes & Glucose Panel (Vitreous)	Chloride, Creatinine, Glucose, Potassium, Sodium, and Urea Nitrogen	Fluid: \$62

1919FL Electrolytes & Glucose Panel (Vitreous), Fluid scope of testing:

Screening Compound	Method	Reporting Limit
Chloride (Vitreous Fluid)	Chemistry Analyzer	70 mmol/L
Creatinine (Vitreous Fluid)	Colorimetry	0.05 mg/dL
Glucose (Vitreous Fluid)	Chemistry Analyzer	35 mg/dL
Potassium (Vitreous Fluid)	Chemistry Analyzer	1 mmol/L
Sodium (Vitreous Fluid)	Chemistry Analyzer	80 mmol/L
Urea Nitrogen (Vitreous Fluid)	Chemistry Analyzer	3 mg/dL

Acode	Description	Scope	Test Price
1611B	Tetrafluoroethane and Difluoroethane Panel, Blood	1,1-Difluoroethane, 1,1,1,2-Tetrafluoroethane	Blood: \$351

1611B Tetrafluoroethane and Difluoroethane Panel, Blood scope of testing:

Screening Compound	Method	Reporting Limit
1,1-Difluoroethane	Gas Chromatography/MassSpectrometry(GC/MS)	0.14 mcg/mL
1,1,1,2-Tetrafluoroethane	Gas Chromatography/MassSpectrometry(GC/MS)	0.14 mcg/mL



Acode	Description	Scope	Test Price
1002B	Carbon Monoxide Exposure Panel, Blood	Carboxyhemoglobin (COHb)	Blood: \$123

1002B Carbon Monoxide Exposure Biouptake Screen, Blood scope of testing:

Confirmation Compound	Confirmation Method	Confirmation Reporting Limit	Screening Method
Carboxyhemoglobin	GC/MS	2 %Saturation	Spectrophotometry (SP)

## **SCHEDULE C**

### **Reports**

All laboratory reports supplied by Provider shall be in full compliance with the best practices in forensic science reporting under Provider's accreditation bodies. Provider's reports include: case number, date of service, specimen type, name of decedent, date of birth. Regarding the results section of the toxicology report, Provider's report includes the description of testing performed, all quantitative results, interpretive comments on toxic ranges of compounds, methods of testing, complete sample identification, and the name of board certified F-ABFT Laboratory Director.

Laboratory reports shall include a summary of all positively identified substances with quantitative results of parent drug compounds and related metabolites. Reports will include the analytical methodology, minimum reporting limit, specimen type used for analysis and general reference comments related to postmortem concentrations of positively identified substances.

Reports are available electronically in a secure PDF format. The electronic reports are posted on Provider's secure Client Portal as soon as the final report is reviewed and completed. Multiple users from the same organization can be notified via e-mail when laboratory reports are available and sign in with their own unique designated user ID/password to access laboratory reports. Reports are archived indefinitely on Provider's Client Portal and can be sorted by patient name, case ID number, date of service, date of birth, sex or accession number for retrieval.

Secure Socket Layer (SSL) encryption is activated when results are displayed. All laboratory reports received are encrypted and cannot be intercepted during transmission.

Preliminary reporting for urgent cases and inquiries is available through direct contact of Provider's client support services department with a verbal discussion with a toxicologist reviewing the case, as necessary. Files concerning the results of specimen analysis will be retained by the Laboratory for a minimum of seven (7) years from the date of issue.

Provider shall work with Dane County Information Management to integrate their case management system in the first quarter of 2020 to allow results to be uploaded into this system.

No penalties shall be assessed against provider during the terms of this contract.